Ligand-drug conjugate of camptothecin analogue, intermediate, preparation method, pharmaceutical composition and application thereof

By developing water-soluble camptothecin analogue conjugates that are linked to cell-binding molecules, the problem of low solubility of camptothecin compounds has been solved, achieving efficient and stable cancer treatment and reducing systemic toxicity side effects.

CN119013024APending Publication Date: 2024-11-22SHANGHAI MICURX PHARMACEUTICAL CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380033216.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-21
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing camptothecin compounds have low solubility in antibody-drug conjugates, leading to aggregation and systemic side effects, which limits their application in cancer treatment.

Method used

A series of water-soluble camptothecin analogue conjugates were developed. By linking with cell-binding molecules, stable conjugates are formed, ensuring efficient release of camptothecin analogues within disordered cells and providing cytotoxicity.

Benefits of technology

It improves the water solubility and cyclic stability of camptothecin analogues, enhances the targeted therapeutic effect on cancer cells, and reduces systemic toxicity side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013024A_ABST
    Figure CN119013024A_ABST
Patent Text Reader

Abstract

The present application relates to conjugates of cell-binding molecules of formula (I) with novel camptothecin analogs. The invention also provides a method for preparing the conjugate of the camptothecin analogue and the cell binding agent, and a method for applying the conjugate to cancer targeted therapy.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 336,995 (filed on April 29, 2022), the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present application provides a conjugate of a camptothecin analog and a cell-surface receptor-binding molecule for targeted therapy, and a pharmaceutical composition comprising such a conjugate. The present application also provides a camptothecin analog, an intermediate of the conjugate of the camptothecin analog, and a method for preparing the same. The present application also provides a camptothecin analog, a conjugate of a camptothecin analog, a pharmaceutical composition comprising a camptothecin analog, and a pharmaceutical composition comprising a conjugate of a camptothecin analog and a cell-binding molecule for use in targeted therapy of cancer. Background Art

[0003] Cancer is the leading cause of death worldwide. Surgery, chemotherapy, radiotherapy, and targeted therapy are the standard of care treatments. Despite its widespread use, the use of most chemotherapies is limited by adverse side effects, primarily through effects on cells outside the tumor and its environment, leading to systemic toxicity and a narrow therapeutic window. The discovery of the unique composition of cancer cell surfaces, combined with an understanding of the strong and selective interactions between antibodies and cell surface antigens, has paved the way for the use of antibodies as targeted delivery agents for chemotherapy, including highly toxic drugs (Drago, JZ et al., Nat. Rev. Clin. Oncol. 2021.; Khongorzul, P. et al., Mol. Cancer Res. 2020, 18, 3–19.; Joubert, N. et al.; The Last Decade. Pharmaceuticals 2020, 13, 245.; Ravi VJ Chari et al., Angew. Chem. Int. Ed. 2014, 53, 3796–3827.). The resulting molecular entity, also known as an antibody-drug conjugate (ADC), consists of three main parts: an antibody responsible for selectively recognizing cancer cell surface antigens that enable the internalization of the ADC, a drug payload responsible for killing cancer cells once released into the body, and a linker that connects the antibody and payload moieties.

[0004] Antibody-drug conjugates (ADCs) combine selective targeting of tumor cells through antigen-directed recognition and potent cell-killing through cytotoxic payloads, and have become effective therapeutic approaches for treating various cancers in recent years (Nature review drug discovery, 2013, 12, 329-332). The first ADC (Mylotarg) was approved in 2000 (after being delisted in 2010, it was reapproved in 2017), the second ADC (Adcetris) was approved under accelerated approval in 2011, and fully approved in 2015. The third (Kadcyla) and fourth (Besponsa) ADCs were approved in 2013 and 2017, respectively. Kadcyla is the first ADC approved for the treatment of solid tumors. Since 2019, more than a dozen ADCs have been approved, and more than 100 ADCs are in clinical development.

[0005] It is known that the payload-linker component in ADC plays a key role in the uniformity, circulation stability, pharmacokinetic characteristics, tolerability and overall therapeutic effect of ADC (Acchionea, M. et al., mAbs. 2012, 4, 362.; Zhao, RY et al., J. Med. Chem. 2011, 54, 3606). Despite extensive research to improve these properties, most payloads used to date include DNA damaging agents (such as calicheamicin, PBD, and duocarmysins), microtubule disruptors (such as maytansines, such as DM1 or DM4; auristatins, such as MMAE or MMAF; tubulysins), and topoisomerase inhibitors (such as camptothecins, such as Dxd or SN-38) (Leung, D., et al., Antibodies (Basel). 2020, 9, 2.; Khongorzul, P., et al., Mol. Cancer. Res., 2020, 18, 3.; Chau, CH, et al., Lancet. 2019, 394, 793.).

[0006] Among these payloads, camptothecin compounds have been shown to be a promising option with a wider therapeutic index than many other payloads used for ADC construction. Two approved ADCs, Enhertu and Trodelvy, use camptothecin payloads Dxd and SN-38, respectively, and have demonstrated significant clinical benefits (progression-free survival (PFS) and overall survival (OS)) for solid tumors in many clinical trials (Pondé, N., et al., Curr Treat Options Oncol. 2019, 20, 37.; Kaplon, H., et al., Mabs. 2020, 12, 1703531.). Camptothecin can induce cell death by interacting with the DNA enzyme topoisomerase I and then accumulating a reversible enzyme-camptothecin-DNA ternary complex.

[0007] Camptothecin is a potent antitumor antibiotic isolated in 1958 from an extract of Camptotheca acuminata, a plant that has been widely used in traditional Chinese medicine for hundreds of years. Many camptothecin analogs have been disclosed, such as those shown below:

[0008] Camptothecin and most of its analogs are extremely insoluble in physiological buffers and have shown high adverse drug reactions in preliminary clinical trials since the 1970s. The low solubility of camptothecin can cause their ADC conjugates to aggregate (Burke, P., et al. Bioconjugate Chem. 2009, 20, 6, 1242), which is problematic for large-scale manufacturing and production, and may cause systemic side effects caused by aggregation. So far, the U.S. FDA has only approved three water-soluble camptothecin analogs: topotecan, irinotecan and belotecan for cancer treatment (Palakurthi, S., Expert Opin Drug Deliv. 2015, 12 (12), 1911). Most of the camptothecin payloads used for ADC development so far have low solubility, which further limits the ratio of drug to antibody and leads to low efficacy.

[0009] The present application provides a series of ligand-drug conjugates of camptothecin analogs. Summary of the invention

[0010] The present application provides conjugates (couplings) of camptothecin analogs connected to cell-binding molecules, camptothecin analog-linker compounds and camptothecin analogs, methods for preparing them and methods for using them, and intermediates for preparing them. The camptothecin analog conjugates of the present application are water-soluble, stable in circulation, and provide high cytotoxicity once free camptothecin analogs or metabolites of camptothecin analog-linker compounds are released from the conjugates near or in disordered cells.

[0011] Aspect 1: These compounds have the general formula I: or a pharmaceutically acceptable salt or solvate thereof, in: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 5 to 8 membered heterocycloalkyl or 5 to 8 membered heteroaryl with a heteroatom of 1 to 2 heteroatom; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each “C 1 -C 8 "alkyl" is independently optionally substituted by 1-3 R 9 replace; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 6 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 6 Alkyl)C(O)O-, (C 1 -C 6 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; Each R 1 and each R 2 Independently selected from H, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl; or each pair of R 1 and R 2 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each R 1 , R 2 and R 1 / R 2 The ring groups are independently optionally substituted with 1 to 4 R 9 replace; n 3 is an integer selected from 0 to 6; X 1 does not exist; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 Contains one or more independently selected from -O-, -S-, -NH-, C 1 -C 6 Alkylene, C 3 -C 6A group consisting of a cycloalkylene group, an arylene group and a heteroarylene group; wherein X 2 Connected to the formula (I) The terminal group is O or S; C 1 -C 6 Alkylene, C 3 -C 6 Each of the cycloalkylene, arylene and heteroarylene groups is independently optionally substituted with 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and the group consisting of: halogen, hydroxyl, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl, wherein C 1 -C 6 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form oxo, 3 to 6-membered cycloalkyl or 4 to 8-membered heterocycloalkyl; wherein each of the 3 to 6-membered cycloalkyl and the 4 to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 Replacement; R 4 , R 5 , R 6 , R 7 and R 8 The remainder of the moiety in each occurrence is independently selected from H and the group consisting of halogen, hydroxyl, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl, wherein C 1 -C 6 Alkyl, C3 -C 6 Cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 4 R 9 Replacement; R 9 Each occurrence is independently selected from halogen, oxo, hydroxy, cyano, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 When the groups are attached to the same carbon, they form a spiro-C 3 -C 6 Cycloalkyl; wherein C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 6 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C 1 -C 3 Alkyl substitution; n 1 and n 2 are each independently an integer selected from 0, 1, 2, 3 and 4; provided that n 1 +n 2 is 2, 3, 4 or 5; and n is an integer selected from 0 and 1. In some embodiments, when one R 4 and an R 5 When R is taken together with the atoms to which they are attached to form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl, 4 and R 5 Located on different but adjacent carbon atoms; when one R 6 and an R 7 When R is taken together with the atoms to which they are attached to form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl, 6 and R 7 Located on different but adjacent carbon atoms; wherein each of the 3 to 6-membered cycloalkyl and the 4 to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 replace.

[0012] In some embodiments or aspects of the present application, the composition or method is provided that the claim does not include any of the following substructures:

[0013] Embodiment A: In some embodiments of the present application, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein n 1 and n 2 is an integer independently selected from 0, 1 and 2, and provided that n 1 +n 2 ≥2; all other variables are as defined in Aspect 1.

[0014] Aspect 2: In some embodiments of the present application, the provided ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is a compound of formula (II) or a ligand-drug conjugate or a medically acceptable salt or solvate thereof: Where: Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 、n 1 and n 2 As defined in formula (I) in Aspect 1 or as defined in Embodiment A.

[0015] Aspect 2-A: In some embodiments of the present application, the provided ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is a compound of formula (IIa) or a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof: Where: Y, Z, R 3 , each R 4 (independently), each R 6 (independently), R 5 , R 7 , R 8 , X 1 and X 2 As defined in formula (I) in aspect 1; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, Y, Z, R 3 , each R 4(independently), each R 6 (independently), R 7 , R 9 and X 2 As defined in formula (I) in aspect 1; and wherein X 1 does not exist; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl, provided that R 4 and R 5 nor forming a ring, wherein the 3- to 6-membered cycloalkyl group and the 4- to 8-membered heterocycloalkyl group are optionally substituted by 1 to 3 R 9 Replacement; R 8 Selected from H and halogen, hydroxyl, C 1 -C 6 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 6 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 Replacement; and 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a 2, 3, or 4.

[0016] Aspect 3: In some embodiments of the present application, the provided ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is according to formula (III): in: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 5 to 8 membered heterocycloalkyl or 5 to 8 membered heteroaryl with a heteroatom of 1 to 2 heteroatom; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each “C 1 -C 8 "alkyl" is optionally substituted by 1 to 3 R 9 replace; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 Alkyl)C(O)O-, (C 1 -C 8 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; Each R 1 and each R 2 Independently selected from H, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl; or each pair of R 1 and R 2 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each R 1 , R2 and R 1 / R 2 The ring groups are independently optionally substituted with 1 to 4 R 9 replace; n 3 is an integer selected from 0 to 6; X 1 does not exist; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 Contains one or more independently selected from -O-, -S-, -NH-, C 1 -C 8 Alkylene, C 3 -C 6 A group consisting of a cycloalkylene group, an arylene group and a heteroarylene group; wherein X 2 The terminal group connected to L is O or S; 1 -C 8 Alkylene, C 3 -C 6 Each of the cycloalkylene, arylene and heteroarylene groups is independently optionally substituted with 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form oxo, 3 to 6-membered cycloalkyl or 4 to 8-membered heterocycloalkyl; wherein each of the 3 to 6-membered cycloalkyl and the 4 to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 Replacement; R 4 , R 5 , R 6 , R 7 and R 8 The remainder of the moiety is independently selected at each occurrence from H and halogen, hydroxyl, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heterocyclyl are independently optionally substituted by 1 to 4 R 9 replace; R 9 Each occurrence is independently selected from halogen, oxo, hydroxy, cyano, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 The group consisting of alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 When the groups are attached to the same carbon, they form a spiro-C 3 -C 6 Cycloalkyl; wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C1 -C 3 Alkyl substitution; n 1 and n 2 are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2 is 2, 3, or 4; and n is an integer selected from 0 and 1; T is the targeting or binding ligand; L is a releasable linker; m is an integer or a fraction selected from 1 to 10.

[0017] Embodiment B: In some embodiments of the present application, the compound of formula III or a pharmaceutically acceptable salt or solvate thereof, wherein n 1 and n 2 is an integer independently selected from 0, 1 and 2, and provided that n 1 +n 2 ≥2; all other variables are as defined in Aspect 3.

[0018] Aspect 3-A: In some embodiments of the present application, the provided ligand drug conjugate or a pharmaceutically acceptable salt or solvate thereof is according to formula (IIIa): Where: Y, Z, R 1 , R 2 , R 3 , each R 4 (independently), each R 6 (independently), R 5 , R 7 , R 8 , X 1 , X 2 , L, T, m and n are as defined in formula (III) in aspect 3; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, Y, Z, R 1 , R 2 , R 3 , each R 4 (independently), R 5 , each R 6 (independently), R 7 , X 2 , L, T, m and n are as defined in Formula (III) in Aspect 3; and wherein X 1 does not exist; or X1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl, provided that R 4 and R 5 nor forming a ring, wherein the 3- to 6-membered cycloalkyl group and the 4- to 8-membered heterocycloalkyl group are optionally substituted by 1 to 3 R 9 Replacement; R 8 Selected from H and halogen, hydroxyl, C 1 -C 6 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 6 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 Replace; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, R 1 and R 2 Each is hydrogen.

[0019] Aspect 3-B: In some embodiments of the present application, the provided ligand drug conjugate or a pharmaceutically acceptable salt or solvate thereof is according to formula (IIIb): Where: Y, Z, R 1 , R 2 , R 3 , X 2 , L, T, m and n are as defined in Formula (IIIa) and any embodiment thereof in Aspect 3-A; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 Replace; X 1 Does not exist;1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, R 1 and R 2 Each is hydrogen, for

[0020] In some embodiments of the present application, the provided ligand drug conjugate of any one of formula (I), (II), (IIa), (III) and (IIIa) or a pharmaceutically acceptable salt or solvate thereof includes the definitions in aspect 1, embodiment A, aspect 2, aspect 2-A, aspect 3, aspect 3-A and embodiment B, wherein: In formula I, II and III and in formula IIa and IIIa is a structure selected from the following:

[0021] In some embodiments, the structure of any one of Formula (I), (II), (IIa), (III) and (IIIa), or a pharmaceutically acceptable salt or solvate thereof, includes as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, wherein In formula I, II and III and in formula IIa and IIIa Select from the following structures:

[0022] In some embodiments, the structure of any one of Formula (I), (II), (IIa), (III) and (IIIa), or a pharmaceutically acceptable salt or solvate thereof, includes as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, wherein In formula I, II and III and in formula IIa and IIIa Select from the following structures:

[0023] In some embodiments, the structure of any one of Formula (I), (II), (IIa), (III) and (IIIa), or a pharmaceutically acceptable salt or solvate thereof, includes as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, wherein In formula I, II and III and in formula IIa and IIIa Select from the following structures:

[0024] In some embodiments, the structure of any one of Formula (I), (II), (IIa), (III) and (IIIa), or a pharmaceutically acceptable salt or solvate thereof, includes as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, wherein In formula I, II and III and in formula IIa and IIIa Select from the following structures:

[0025] In another preferred embodiment of the present application, in the ligand drug conjugate according to the present application or a pharmaceutically acceptable salt or solvate thereof, including any one of formula (I), (II), (IIa), (III), (IIIa) and (IIIb) and any embodiment thereof, including as defined in aspect 1, embodiment A, aspect 2, aspect 2-A, aspect 3, aspect 3-A and embodiment B, the linker unit L is -L 1 -L 2 -L 3 -L 4 -,in L 1 Selected from the group consisting of: -CH 2 -C(O)-NR 10 -WC(O)-, -C(O)-WC(O)-, and -W-, where W and W 1 Independently selected from the group consisting of: C 1 -C 8 Alkylene, -(C 1 -C 8 alkylene)-cycloalkylene, arylene, heteroarylene and straight chain heteroalkylene, wherein the straight chain heteroalkylene contains 1 to 8 carbon atoms and 1 to 3 heteroatoms selected from N, O, S, SO and SO 2 wherein said-(C 1 -C 8 Each of the following groups is independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the above-provided L 1The left side of each of the groups is connected to T; L 2 Selected from the group consisting of: -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds, where p 1 is an integer selected from 1 to 20 at each occurrence; L 2 Preferably a chemical bond; wherein the above provided L 2 The left side of each group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Selected from the group consisting of: -NR 12 (CR 13 R 14 ) t -、-C(O)NR 12 -、-C(O)NR 12 (CH) t -、 and a chemical bond, wherein t at each occurrence is an integer selected from 1 to 6; L 4 Preferably -NR 12 (CR 13 R 14 ) t ; wherein each L provided above 4 The left side of each group is connected to L3 on the right side, and L 4 The right side of each group is connected to X 2 ; R 10 , R 11 and R 12 are each independently selected from H, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 13 and R 14 are each independently selected from H, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 Selected from -CH 2 CH 2 SO 2 CH 3 and -CH 2 CH 2 N(CH 3 ) 2 .

[0026] In another preferred embodiment of the present application, including any one of Formula (I), (II), (IIa), (III), (IIIa) and (IIIb) and any embodiment thereof, including the ligand-drug conjugate as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, or a pharmaceutically acceptable salt or solvate thereof, the linking unit L 1 Selected from the group consisting of: -CH 2 -C(O)-NR 10 -(CH 2 )s 3 -C(O)- (where the left side of the group is attached to T), -C(O)- (CH 2 )s 4 -C(O)- (where the left side of the group is attached to T) and -C 6 H 4 -, where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; s 3 is an integer selected from 1 to 8; s 4 is an integer selected from 1 to 8; wherein s 1 5 is preferred; L 2 Selected from the group consisting of: -NR 11 (CH 2 CH 2 O) p 1CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds; where p 1 is an integer selected from 6 to 12 at each occurrence; L 2 Preferably, a chemical bond; wherein the L provided above 2 The left side of each group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids. The amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), glutamic acid (E) and aspartic acid (N); preferably a peptide residue consisting of 1, 2 or more phenylalanine and glycine; more preferably a peptide residue consisting of 4 amino acids; most preferably a peptide residue consisting of GGFG; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 For-NR 12 (CR 13 R 14 ) t -, R 12 is H or alkyl, R 13 and R 14 Each is independently selected from H and alkyl, t is 1 or 2; L 4 Optionally -NR 12 CR 13 R 14 -; or L 4 Preferably -NHCH 2 -; wherein the above-mentioned L 4 The left side of each group is connected to L 3 on the right side; and L 4 The right side of each group is connected to X 2 ; R 10 , R11 and R 12 are each independently selected from the group consisting of H, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; and R 13 and R 14 Each is independently selected from the group consisting of H, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl.

[0027] Aspect 4: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, wherein the compound is of formula (IV): Where: Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 , L 2 , L 3 , L 4 , W, n 1 、n 2 , T and m are as defined in formula (III) and any of its embodiments, including as defined in embodiment B, and n 3 is an integer selected from 0 to 6.

[0028] Aspect 4-A: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, wherein the compound has formula (IVa): Where: Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 , L 2 , L 3 , L 4 , W, n 1 、n 2a , T and m are as defined in formula (IIIa) and any embodiment thereof, n 3 is an integer selected from 0 to 6.

[0029] In some embodiments of the present application, a ligand-drug conjugate of formula (IV) or (IVa) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: In formula (IV) and in formula (IVa) is a structure selected from the following:

[0030] In some embodiments, the structure of any one of Formula (IV) or (IVa), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (IV) and (IVa) Select from the following structures:

[0031] In some embodiments, the structure of formula (IV) or (IVa), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (IV) and in formula (IVa) Select from the following structures:

[0032] In some embodiments, the structure of formula (IV) or (IVa), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (IV) and in formula (IVa) Select from the following structures:

[0033] In some embodiments, the structure of formula (IV) or (IVa), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (IV) and in formula (IVa) Select from the following structures:

[0034] In some embodiments, the ligand-drug conjugate includes but is not limited to: or a pharmaceutically acceptable salt or solvate thereof; wherein T and m are as defined in formula (III) or (IIIa) and any of its embodiments, including as defined in embodiment B; wherein further embodiments of T are provided below.

[0035] In some embodiments of the present application, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is a targeting antibody or ligand that binds to an antigen; wherein the antibody is selected from a chimeric antibody, a humanized antibody and a human antibody; optionally, wherein T is a monoclonal antibody.

[0036] In some embodiments of the present application, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is selected from anti-Her2 (ErbB2) antibody, anti-EGFR antibody, anti-B 7 H 3 Antibodies, anti-c-MET antibodies, anti-Her3 (ErbB3) antibodies, anti-Her4 (ErbB4) antibodies, anti-CD20 antibodies, anti-CD22 antibodies, anti-CD30 antibodies, anti-CD33 antibodies, anti-CD44 antibodies, anti-CD56 antibodies, anti-CD70 antibodies, anti-CD73 antibodies, anti-CD105 antibodies, anti-CEA antibodies, anti-A33 antibodies, anti-Cripto antibodies, anti-EphA2 antibodies, anti-G250 antibodies, anti-MICI antibodies, anti-Lewis Y antibodies, anti-VEGFR antibodies, anti-GPNMB antibodies, anti-integrin antibodies, anti-PSMA antibodies, anti-Tenascin-C antibodies, anti-SLC44A4 antibodies or anti-mesothelin antibodies, and anti-ROR1 antibodies or antigen-binding fragments.

[0037] In some embodiments of the present application, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is selected from Trastuzumab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96 and Glembatumumab, or a fragment that binds to an antigen.

[0038] In some embodiments, the ligand-drug conjugates include but are not limited to: or a pharmaceutically acceptable salt or solvate thereof; wherein m is as defined in formula (III) or (IIIa) and any embodiment thereof, including as defined in the example mode.

[0039] Aspect 5: In some other embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, wherein the compound is of formula (V): Where: Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 、n 1 and n 2 As defined in formula (III) and any embodiment thereof, including as defined in embodiment B, and L 2 Selected from -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds, where p 1is an integer selected from 1 to 20; L 2 Preferably, a chemical bond; wherein the L provided above 2 The left side of each group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Selected from the group consisting of: -NR 12 (CR 13 R 14 ) t -、-C(O)NR 12 -、-C(O)NR 12 (CH) t -、 and a chemical bond, wherein t is an integer selected from 1 to 6; L 4 Preferably -NR 12 (CR 13 R 14 ) t -; wherein the L provided above 4 The left side of each group is connected to L 3 on the right side, and L 4 The right side of each group is connected to X 2 ; R 11 and R 12 are each independently selected from the group consisting of H, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 13 and R 14 are each independently selected from the group consisting of H, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 Selected from -CH 2 CH 2 SO 2 CH 3 and -CH 2 CH 2 N(CH 3 ) 2 ; W is selected from the group consisting of: C 1 -C 8 Alkylene, -(C 1 -C8 alkylene)-cycloalkylene, arylene, heteroarylene and straight-chain heteroalkylene, wherein the straight-chain heteroalkylene contains 1 to 8 carbon atoms and 1 to 3 heteroatoms selected from N, O, S, SO and SO 2 wherein said-(C 1 -C 8 Each of the alkylene)-cycloalkyl-, straight chain heteroalkylene, arylene and heteroarylene groups is independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; and n 3 An integer selected from 0 to 6. In some embodiments, L 2 Selected from -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds; where p 1 An integer selected from 6 to 12 at each occurrence; L 2 Preferably, a chemical bond; wherein each L provided above 2 The left side of the group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids. The amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), glutamic acid (E), and aspartic acid (N); preferably, it is a peptide residue consisting of 1, 2 or more phenylalanine and glycine; more preferably, it is a peptide residue consisting of 4 amino acids; most preferably, it is a peptide residue consisting of GGFG; wherein, the L provided above 3 The left side of each group is connected to L 2 ; L4 For-NR 12 (CR 13 R 14 ) t -, R 12 is H or alkyl, R 13 and R 14 Each is independently selected from H and alkyl, t is 1 or 2; L 4 Optionally -NR 12 CR 13 R 14 -; or L 4 Preferably -NHCH 2 -; wherein the above-mentioned L 4 The left side of each group is connected to L 3 on the right side, and L 4 The right side of each group is connected to X 2 ; R 11 and R 12 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; and R 13 and R 14 Each is independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl.

[0040] In aspect 5-A: In some other embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, wherein the compound is of formula (Va): Where: Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 、n 1 and n 2a As defined in formula (IIIa) and any embodiment thereof, L 2 , L 3 , L 4 , W and n 3 As defined in formula (V) and its embodiments in aspect 5.

[0041] In some embodiments of the present application, a ligand-drug conjugate of formula (V) or (Va) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: In formula (V) and formula (Va) is a structure selected from the following:

[0042] In some embodiments, the structure of any one of Formula (V) or (Va), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (V) and (Va) Select from the following structures:

[0043] In some embodiments, the structure of Formula (V) or (Va), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (V) and (Va) Select from the following structures:

[0044] In some embodiments, the structure of Formula (V) or (Va), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (V) and (Va) Selected from the following structures,

[0045] In some embodiments, the structure of Formula (V) or (Va), or a pharmaceutically acceptable salt or solvate thereof, wherein In formula (V) and (Va) Select from the following structures

[0046] In some embodiments, the compounds include but are not limited to: or a pharmaceutically acceptable salt or solvate thereof.

[0047] Aspect 6: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein the compound of formula (VI): in: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 6 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 5 to 8 membered heterocycloalkyl or 5 to 8 membered heteroaryl with a heteroatom of 1 to 2 heteroatom; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each “C 1 -C 8 "alkyl" is independently optionally substituted by 1-3 R 9 replace; Each R 1 and each R 2 Independently selected from H, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl, heteroaryl; or each pair of R 1 and R 2 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each R 1 , R 2 and R 1 / R 2The ring groups are independently optionally substituted with 1 to 4 R 9 replace; n 3 is an integer selected from 0 to 6; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 Alkyl)C(O)O-, (C 1 -C 8 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; X 1 does not exist; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 Contains one or more independently selected from -O-, -S-, -NH-, C 1 -C 8 Alkylene, C 3 -C 6 A group consisting of a cycloalkylene group, an arylene group and a heteroarylene group; wherein X 2 Connect to –X 2 The terminal group of H in -H is O or S; C 1 -C 8 Alkylene, C 3 -C 6Each of the cycloalkylene, arylene and heteroarylene groups is independently optionally substituted with 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form oxo, 3 to 6-membered cycloalkyl or 4 to 8-membered heterocycloalkyl; wherein each of said 3 to 6-membered cycloalkyl and 4 to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 Replace; and the remaining R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heterocyclyl are independently optionally substituted by 1 to 4 R 9 replace; R 9 is independently selected at each occurrence from halogen, oxo, hydroxy, cyano, C 1 -C 8Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 The group consisting of alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 The groups, when attached to the same carbon, together with the carbon to which they are attached, form a spiroC 3 -C 6 Cycloalkyl; wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C 1 -C 3 Alkyl substitution; n 1 and n 2 are each independently selected from an integer of 0, 1, 2, 3 and 4, provided that n 1 +n 2 is 2, 3 or 4; and n is an integer selected from 0 and 1.

[0048] Embodiment C: In some embodiments of the present application, the compound of formula VI or a pharmaceutically acceptable salt or solvate thereof, wherein n 1 and n 2 is an integer independently selected from 0, 1 and 2, and provided that n 1 +n 2 ≥2; all other variables are as defined in Aspect 6.

[0049] Aspect 6-A: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein the compound of formula (VIa): Where: Y, Z, R 1 , R 2 , R 3 , each R 4 (independently), each R 6 (independently), R5 , R 7 , R 8 , X 1 and X 2 As defined in formula (VI) in aspect 6; n 3 is an integer selected from 0 to 6; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, Y, Z, R 1 , R 2 , R 3 , each R 4 (independently), R 5 , each R 6 (independently), R 7 and X 2 As defined in formula (VI) in aspect 6; and wherein X 1 does not exist; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl, provided that R 4 and R 5 nor forming a ring, wherein the 3- to 6-membered cycloalkyl group and the 4- to 8-membered heterocycloalkyl group are optionally substituted by 1 to 3 R 9 Replacement; R 8 Selected from H and halogen, hydroxyl, C 1 -C 6 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 6 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 Replace; n 3 is an integer selected from 0 to 6; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4, provided that n 1 +n 2a is 2, 3 or 4. In some embodiments, R 1 and R 2 Each is hydrogen.

[0050] Aspect 7: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, which is a compound of formula (VII): Where: Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 、n 1 and n 2 As defined in formula (VI), including as defined in embodiment C.

[0051] Aspect 7-A: In some embodiments of the present application, a compound or a pharmaceutically acceptable salt or solvate thereof is provided, optionally as a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, which is a compound of formula (VIIA): Where: Y, Z, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 、n 1 and nn 2a As defined in formula (VIa).

[0052] In some embodiments, the following compounds are excluded from the compounds of formula (VI), (VIa), (VII) and (VIIa):

[0053] In some embodiments of the present application, the structure of any one of Formula II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII and VIIa, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y and Z are independently selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; R 3 Selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; X 1 does not exist; X 2is-O-; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H, halogen and C 1 -C 8 alkyl; n 1 and n 2a are each independently an integer selected from 0, 1, 2 and 3; provided that n 1 +n 2a 2, 3, or 4.

[0054] In some embodiments of the present application, a compound of any one of formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, is provided, wherein: In formula (VI) and (VII) and in formula (VIa) and (VIIa) is a structure selected from the following structures,

[0055] In some embodiments of the present application, a compound of any one of formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, is provided, wherein: In formula (VI) and (VII) and in formula (VIa) and (VIIa) Select from the following structures:

[0056] In some embodiments of the present application, a compound of any one of formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, is provided, wherein: In formula (VI) and (VII) and in formula (VIa) and (VIIa) Select from the following structures:

[0057] In some embodiments of the present application, a compound of any one of formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, is provided, wherein: In formula (VI) and (VII) and in formula (VIa) and (VIIa) Select from the following structures:

[0058] In some embodiments of the present application, a compound of any one of formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, is provided, wherein: In formula (VI) and (VII) and in formula (VIa) and (VIIa) Select from the following structures:

[0059] In some embodiments, provided is a compound of any one of Formula (VI), (VIa), (VII) and (VIIa) or a pharmaceutically acceptable salt or solvate thereof and any embodiment thereof, including embodiment C, selected from: or tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof.

[0060] In another embodiment, the cell-surface binding molecule T can be any type currently known, or become a known cell binding ligand, such as a peptide and a non-peptide. Typically, the cell-binding molecule T is an antibody; a single-chain antibody; an antibody fragment that binds to the target cell; a monoclonal antibody; a single-chain monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to the target cell; a domain antibody; a domain antibody fragment that binds to the target cell; adnectins that mimic antibodies, DARPins; lymphokines; hormones; vitamins; growth factors; colony stimulating factors; or a nutrient transport molecule (transferrin), a binding peptide, a protein, an antibody, or a small molecule, a polymer, a dendrimer, a liposome, a nanoparticle, a vesicle, a (virus) capsid attached to albumin. Preferably, the binding molecule T is a monoclonal antibody.

[0061] The present application also provides compounds of formula (I), (II), (IIa), (III), (IIIa) and (IIIb) and any embodiments thereof, including compounds as defined in Aspect 1, Embodiment A, Aspect 2, Aspect 2-A, Aspect 3, Aspect 3-A and Embodiment B, or pharmaceutically acceptable salts or solvates thereof, wherein the compound is a tautomer, a racemate, a racemate, an enantiomer, a diastereomer or a mixture thereof.

[0062] Another aspect of the present application provides a method for preparing a ligand-drug conjugate of formula (I), (II), (IIa), (III), (IIIa) and (IIIb) and any embodiment thereof, or a pharmaceutically acceptable salt or solvate thereof, and optionally a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof.

[0063] Another aspect of the present application further relates to a pharmaceutical composition comprising a therapeutically effective amount of 1) the ligand-drug conjugate or compound of the present application or a pharmaceutically acceptable salt or solvate thereof, and optionally a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, and 2) one or more pharmaceutically acceptable carriers, diluents or excipients.

[0064] Another aspect of the present application also relates to 1) the use of the ligand-drug conjugate or compound of the present application, or a pharmaceutically acceptable salt or solvate thereof, and optional tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof, or 2) the use of the pharmaceutical composition containing the same drug as according to the present application in the preparation of a medicament for treating or preventing a tumor, preferably, the tumor is a cancer associated with HER2, HER3 or EGFR expression.

[0065] Another aspect of the present application also relates to 1) the use of a ligand-drug conjugate or compound, or a pharmaceutically acceptable salt or solvate thereof, and optionally a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, or 2) the use of a pharmaceutical composition comprising the same drug according to the present application in the preparation of a medicament for treating or preventing cancer, preferably, the cancer is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, Cancer of the pancreas, salivary gland, esophagus, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectum cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, prostate cancer, and lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, or relapsed anaplastic large cell lymphoma).

[0066] The active compound can be formulated into a form suitable for administration by an appropriate route, and the active compound can be in a unit dose form in advance, or in a form that the patient can self-administer by a single dose. The unit dose form of the compound or composition of the present application can be tablets, capsules, cachets, bottle portions, powders, granules, lozenges (tablets), suppositories, reconstituted powders or liquid preparations.

[0067] The dosage of the compound or composition in the treatment method of the present application will generally vary depending on the severity of the disease, the patient's weight and the relative efficacy of the compound. However, as a general guide, a suitable unit dosage may be 0.1 to 1000 mg.

[0068] In addition to the active compound, the pharmaceutical composition of the present application may also contain one or more auxiliary agents, including filters (diluents), binders, wetting agents, disintegrants, excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99 wt% of the active compound.

[0069] The pharmaceutical composition containing active ingredients can be in a form suitable for oral administration, such as tablets, lozenges, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Oral compositions can be prepared according to any known method for preparing pharmaceutical compositions in the art. Such compositions can include adhesives, fillers, lubricants, disintegrants or pharmaceutically acceptable wetting agents, etc. Such compositions can also include one or more components selected from sweeteners, flavorings, coloring agents and preservatives to provide a pleasant and palatable pharmaceutical preparation.

[0070] Aqueous suspensions include the active ingredient in admixture with excipients suitable for the preparation of aqueous suspensions. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.

[0071] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil. Oil suspensions may include a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation.

[0072] The pharmaceutical composition of the present application may also be in the form of an oil-in-water emulsion.

[0073] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable carriers or solvents that may be used are water, Ringer's solution or isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and treated to form a microemulsion. The injectable solution or microemulsion may be introduced into the patient's bloodstream by local intravenous bolus injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compound of the present application. In order to maintain this constant concentration, a continuous intravenous delivery device may be used. Deltec CADD-PLUS TM The 5400 IV Pump is an example of such a device.

[0074] Pharmaceutical composition can be in the form of sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration. According to known technology, this suspension can be prepared with suitable dispersants or wetting agents and suspending agents as mentioned above. Aseptic injection preparation can also be aseptic injection solution or suspension prepared in nontoxic non-intestinal acceptable diluent or solvent. In addition, sterile fixed oil can be used as solvent or suspension medium at an easy speed.

[0075] The compounds of the present application can be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid in the rectum, thereby melting in the rectum to release the drug. These materials include cocoa butter, glycerin gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and their fatty acid esters.

[0076] It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of a particular compound, the age of the patient, the weight of the patient, the general health of the patient, the behavior of the patient, the diet of the patient, the administration time, the administration route, the excretion rate, the drug combination, etc. In addition, the optimal treatment can be verified according to traditional treatment regimens, such as the treatment mode, the daily dose of the compound of formula (I) or the type of its pharmaceutically acceptable salt. BRIEF DESCRIPTION OF THE DRAWINGS

[0077] Figure 1 The results of an in vitro bystander killing assay of target cells SK-BR-3 and GFP-labeled tool cells Flip are shown (Example 70); Figure 2 The results of an in vitro plasma stability study of the ADC are shown (Example 71); Figure 3 The results of the ADC efficacy study on NCI-N87 tumor-bearing nude mice are shown (Example 72); Figure 4 The changes in tumor size produced after 21 days of ADC treatment are shown (Example 72). DETAILED DESCRIPTION

[0078] Unless otherwise specified, all technical and scientific terms used in this application are consistent with the common understanding of ordinary technicians in the field to which this application belongs. Although any methods and materials similar or equivalent to the methods and materials described in this application can be used in the practice or testing of this application, preferred methods and materials are described herein. When describing and interpreting this application, the following terms are used according to the following definitions.

[0079] Unless otherwise stated, the terms used in the specification and claims have the following meanings.

[0080] As used herein, "A" and "an" mean one or more unless the context clearly dictates otherwise.

[0081] "Ligand" refers to a compound that can recognize and bind to an antigen or receptor associated with a target cell. The role of the ligand is to deliver the drug to a target cell population that binds to the ligand. Such ligands include, but are not limited to, protein hormones, lectins, growth factors, antibodies, peptides, or other molecules that can bind to cells. In one embodiment of the present application, for trastuzumab, the ligand is represented by T. The ligand can form a bond with the linker through a heteroatom on the ligand. The ligand is preferably an antibody or an antigen-binding fragment thereof. The antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, a fully humanized antibody, or a mouse antibody. The antibody is more preferably a monoclonal antibody.

[0082] The term "drug" refers to a cytotoxic drug provided herein, which is a chemical molecule that can strongly destroy the normal growth of tumor cells. In principle, all cytotoxic drugs can kill tumor cells at sufficiently high concentrations. However, they may cause apoptosis of normal cells, resulting in serious side effects, or even kill normal cells while killing tumor cells due to lack of specificity.

[0083] The term "linker", "linker unit", "linking fragment" or "linking unit" refers to a chemical structure fragment or bond that is connected to a ligand at one end and to a drug at the other end. 1 To L 4 Indicates that L 1 The end is connected to the ligand, L 4 The end is connected to the drug.

[0084] Linkers, including extension units, spacer units, and amino acid units, can be synthesized by methods known in the art, such as those described in US2005-0238649A1. Linkers can be "cleavable linkers" or "releasable linkers" that facilitate the release of drugs in cells. For example, acid-labile linkers (e.g., hydrazones), protease-sensitive (e.g., peptidase-sensitive) linkers, photo-labile linkers, dimethyl linkers, or disulfide-containing linkers can be used (Chari et al., Cancer Research 52: 127-131 (1992); US Pat. No. 5,208,020).

[0085] The term "ligand-drug conjugate" refers to a biologically active drug connected to a ligand provided in the present application through a stable linking unit. In the present application, the "ligand-drug conjugate" is preferably an antibody-drug conjugate (ADC), which means that a toxic drug is connected to a biologically active monoclonal antibody or antibody fragment through a stable linking unit.

[0086] The three letter codes and one letter codes for amino acids used in this application are as described in J. Biol. Chem, 243, p3558 (1968).

[0087] The term "antibody" refers to immunoglobulins, a four-peptide chain structure linked together by interchain disulfide bonds between two identical heavy chains and two identical light chains. Different immunoglobulin heavy chain constant regions have different amino acid compositions and sequences, and therefore have different antigenicity. Therefore, immunoglobulins can be divided into five types, or immunoglobulin isotypes, namely IgM, IgD, IgG, IgA and IgE, with corresponding heavy chains |i, y, a and e, respectively. Depending on the amino acid composition of the hinge region and the number and position of the heavy chain disulfide bonds, the same type of Ig can be further divided into different subtypes, for example, IgG can be divided into IgG1, IgG2, IgG3 and IgG4. Light chains can be divided into K chains or X chains depending on the constant region. Each of the five types of Ig can have either K or X chains. The antibodies described in the present application are preferably specific antibodies against cell surface antigens on target cells, and non-limiting examples are one or more of the following antibodies: anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-Her3 (ErbB3) antibody, anti-Her4 (ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUC1 antibody, anti-Lewis antibody Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody or anti-mesothelin antibody, preferably trastuzumab (trade name Herceptin), pertuzumab (also known as 2C4, trade name Peijeta), nimotuzumab (Nimotuzumab) (trade name Taixinshe ng), Enoblituzumab, Emibetuzumab, Inetuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96, and Glembatumumab.

[0088] The approximately 110 amino acid sequences adjacent to the N-terminus of the heavy or light chain of an antibody are highly variable and are called the variable region (Fv region); the remaining amino acid sequences adjacent to the C-terminus are relatively stable and are called the constant region. The variable region includes three hypervariable regions (HVRs) and four relatively conserved framework regions (FRs). The three hypervariable regions that determine the specificity of the antibody are also called complementarity determining regions (CDRs). Each light chain variable region (LCVR) or each heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; and the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.

[0089] The antibodies of the present application include murine antibodies, chimeric antibodies, humanized antibodies and fully humanized antibodies, preferably humanized antibodies and fully humanized antibodies.

[0090] The term "murine antibody" in this application refers to an antibody prepared by murines according to the knowledge and skills in the art. In the preparation process, a subject is injected with a specific antigen, and then a hybridoma expressing an antibody with the desired sequence or functional characteristics is isolated.

[0091] The term "chimeric antibody" is an antibody obtained by fusing the variable region of a murine antibody with the constant region of a human antibody, and the chimeric antibody can reduce the immune response induced by the murine antibody. In order to establish a chimeric antibody, a hybridoma secreting a murine-specific monoclonal antibody is established, and the variable region gene is cloned from the murine hybridoma cell; then the constant region gene of the human antibody is cloned as needed; the human constant region gene is connected to the murine variable region gene to form a chimeric gene, which is then inserted into an expression vector; finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system.

[0092] The term "humanized antibody" is also referred to as CDR-transplanted antibody, which refers to antibodies produced by transplanting murine CDR sequences into human antibody variable region frameworks, i.e. antibodies produced in different types of human germline antibody framework sequences. Humanized antibodies can overcome heterologous reactions induced by a large number of murine protein components carried by chimeric antibodies. Such framework sequences can be obtained from public DNA databases or published references covering germline antibody gene sequences. For example, germline DNA sequences of human heavy and light chain-variable region genes can be found in the "VBase" human germline sequence database (available on the World Wide Web at www.mrccpe.com.ac.uk / VBase) and Kabat, EA, et al. 1991Sequences of Proteins of Immunological Interest, 5th Ed. In order to avoid the reduction in activity caused by reduced immunogenicity, the framework sequences in the human antibody variable regions can be subjected to minimal reverse mutations or back mutations to maintain activity. The humanized antibodies of the present application also include humanized antibodies, which are subjected to CDR affinity maturation thereon by phage display. References further describing methods involving humanized murine antibodies include, for example, Queen et al., Proc., Natl. Acad. Sci. USA, 88, 2869, 1991 and Winter and colleagues' method [Jones et al., Nature, 321, 522 (1986), Riechmann et al., Nature, 332, 323-327 (1988), Verhoeyen et al., Science, 239, 1534 (1988)].

[0093] The term "fully humanized antibody" is also called "fully humanized monoclonal antibody", in which the variable region and constant region of the antibody are both from humans, eliminating immunogenicity and side effects. The development of monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully humanized antibodies. The antibody of the present application is a fully humanized monoclonal antibody. The relevant technologies for the preparation of fully humanized antibodies mainly include human hybridoma technology, EBV transformed B lymphocyte technology, phage display technology, transgenic mouse antibody preparation technology, single B cell antibody preparation, etc.

[0094] The term "antigen binding fragment" refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen. It has been shown that fragments of full-length antibodies can be used to achieve the function of binding to an antigen. Examples of binding fragments in the term "antigen binding fragment" include (i) Fab fragments, which are monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bond in the hinge region; (iii) Fd fragments, which consist of VH and CH: domains; (iv) Fv fragments, which consist of the VH and VL domains of a single-armed antibody; (v) a single domain or dAb fragment consisting of a VH domain (Ward et al. (1989) Nature 341: 544-546); and (vi) isolated complementary determining regions (CDRs) or (vii) a combination of two or more isolated CDRs optionally linked by a synthetic linker. In addition, although the VL domain and VH domain of the Fv fragment are encoded by two independent genes, they can be connected by a synthetic linker using a recombinant method to produce a single protein chain of a monovalent molecule formed by pairing the VL and VH domains (called a single-chain Fv (scFv); for example, see Bird et al. (1988) Science: 242: 423-426, and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and functional fragments are screened using the same methods as intact antibodies. The antigen binding site can be produced by recombinant DNA technology or by enzymatic or chemical destruction of intact immunoglobulins. The antibody can be an antibody of a different isotype, such as an IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtype), an IgA1, an IgA2, an IgD, an IgE, or an IgM antibody.

[0095] Fab is an antibody fragment obtained by treating an IgG antibody molecule with papain, which cleaves the amino acid residue at position 224 of the H chain. The Fab fragment has a molecular weight of about 50,000 and has antigen-binding activity, in which about half of the N-terminal side of the H chain and the entire L chain are bound together by a disulfide bond.

[0096] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contributes to antigen binding. Kabat E.A. et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242 provides one of the most commonly used definitions of the six CDRs. As used in this application, the Kabat definition of CDR applies only to CDR1, CDR2 and CDR3 (CDRL1, CDRL2, CDRL3 or L1, L2, L3) of the light chain variable domain, and CDR2 and CDR3 (CDRH2, CDRH3 or H2, H3) of the heavy chain variable domain.

[0097] The term "antibody framework" refers to the portion of a variable domain VL or VH that serves as a scaffold for the antigen binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.

[0098] The terms "specific binding", "selective binding", "selective binding" and "specific binding" refer to the binding of an antibody to an epitope on a predetermined antigen. -7 M affinity (KD) binding, for example, less than about 10 -8 M, 10 -9 M or 10 -10 M or smaller.

[0099] Methods for preparing and purifying antibodies and antigen-binding fragments are well known in the art, such as Cold Spring Harbor Antibody Technical Guide, Chapters 5-8 and 15. Antigen-binding fragments can also be prepared by conventional methods. The antibodies or antigen-binding fragments of the present application are genetically engineered to add one or more human FR regions in the non-human CDR region. Human FR germline sequences can be compared to the IMGT human antibody variable germline gene databases and MOE software, which is derived from the ImMunoGeneTics (IMGT) website at http: / / imgt.cines.fr or the Journal of Immunoglobulins 20011SBN012441351.

[0100] The term "peptide" refers to a compound fragment between amino acids and proteins, consisting of two or more amino acid molecules connected to each other by peptide bonds. Peptides are structural and functional fragments of proteins. Hormones, enzymes, etc. are basically peptides.

[0101] The term "toxin" refers to any substance that may have a deleterious effect on cell growth or proliferation. The toxin may be a small molecule toxin and its derivatives from bacteria, fungi, plants or animals, including camptothecin derivatives such as exatecan, maytansinoid and its derivatives (CN101573384), such as DM1, DM3, DM4, auristatin F (AF) and its derivatives, such as MMAF, MMAE, 3024 (WO2016 / 12790A1, compound 7), diphtheria toxin, exotoxin, ricin A chain, abrin A chain, modec-cin, α-sarcin, Aleutitesfordii toxic protein, dianthin toxic protein, Phytolaca americana toxic protein, protein)(PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and trichothecenes.

[0102] The term "chemotherapeutic agent" refers to a compound that can be used to treat tumors. The definition also includes anti-hormonal drugs that modulate, reduce, block or inhibit the effects of hormones that promote cancer growth, which are usually in the form of systemic or total therapy. They can be hormones. Examples of chemotherapeutic drugs include alkylating agents, such as thiotepa; cyclosphamide; alkyl sulfonates, such as busulfan, improsulfan and piposulfan; aziridines, such as benaodopa and uredepa; aziridines and methylamelamines, including altretamine, triethylenemelamine and trimethylolomelamin e); nitrogen mustards, such as chlorambucil and chlornaphazine; melphalan and novembichin; nitrosoureas, such as carmustine and chlorozotocin; antibiotics, such as aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin C), calicheamicin, carabicin, chromomycin, carzinophilin, actinomycin D, daunorubicin, detorubicin, doxorubicin, epirubicin, esorubicin, idarubicin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin;streptozocin, tuberculocidin, ubenimex, zinostatin, zorubicin; antimetabolites, such as methotrexate, 5-fluorouracil (5-FU); folic acid analogs, such as denopterin, methotrexate, pteropterin, trimetrexate; pterin analogs, such as leucovorin, fenvalerate, fenvalerate, dapoxetine ... analogs, such as fludarabine, 6-mercaptopterin, thiomethopterin, thioguanopterin; pyrimidine analogs, such as ancitabine, datrexate, 6-azuridine, carmofil, doxitluridine, enocitabine, floxuridine; androgen, such as calusterone, dromostanolong propionate, propionate, epitiostanol, aromatase inhibitors (testolactone); antiadrenalines (aminoglutethimide, mitotane, trilostane); folic acid supplements (folate); aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; biasntrene; defbfamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine;Mitoguazone; mitoxantrone; mopidamol; nitracrine; pintostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; razoxane; sizofiran; spirogemanium; tenuazonic acid acid; triaziquone; trichlorrotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; dibromodulcitol; pipobroman; gacytosine; arabinoside; cyclophosphamid e; thiotepa; taxanes, such as paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin and carboplatin; vinblastine; platinum; etoposide; ifbsfamily; mitomycin C C); mitoxantrone; vincristine; vinorelbine; navelbine; novantrone hydrochloride; teniposide; daunorubicin; aminopterin; xeloda; ibandronate; topoisomerase inhibitor RFS2000; difluoromethylomithine; retinoic acid esperamicins; capecitabine;and any pharmaceutically acceptable salts, acids or derivatives of the foregoing. This definition also includes anti-hormonal drugs. ;

[0103] The carbon atom content of various hydrocarbon-containing molecules is indicated by prefixes representing the minimum and maximum number of carbon atoms in the molecule, i.e., the prefix C i-j represents the portion of carbon atoms from integer "i" to integer "j" (inclusive of the carbon atoms indicated by these two integers). Thus, for example, C 1-6 The alkyl group refers to an alkyl group having 1 to 6 carbon atoms (inclusive).

[0104] The term "alkyl" as used in this application refers to a straight or branched saturated hydrocarbon substituent (i.e., a substituent obtained by removing hydrogen from a hydrocarbon group); in one embodiment, it contains 1 to 8 carbon atoms, in another embodiment, it contains 1 to 6 carbon atoms, and in another embodiment, it contains 1 to 3 carbon atoms. Non-limiting examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isopentyl, hexyl, heptyl, octyl, etc. In another embodiment, it contains 1 to 3 carbons and consists of methyl, ethyl, n-propyl and isopropyl. The term "each 'C 1 -C 8 The alkyl group is optionally substituted with 1 to 3 R 9 Substituted", which means that each "C 1 -C 8 The "alkyl" may be 1 to 3 R 9 For example, in the following list, “C 1 -C 8 Alkyl, (C 1 -C 8 Alkyl)NHC(O)O-, (C 1 -C 8 Alkyl)NH-, (C 1 -C 8 alkyl)C(O)O-", each C 1 -C 8 Alkyl groups can be replaced by 1 to 3 R 9 replace.

[0105] The term "alkylene" as used herein refers to a divalent alkyl group as defined herein.

[0106] The term "-alkylene-cycloalkylene-" as used herein refers to an alkylene group, as defined herein, bonded to a cycloalkylene group, as defined herein.

[0107] The term "alkoxy" refers to an -OR group, wherein R is an alkyl group as defined herein (i.e., a substituent obtained from a hydrocarbon alcohol by removing hydrogen from OH); in one embodiment, it contains 1 to 6 carbon atoms. Non-limiting examples of such substituents include methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy and tert-butoxy), pentoxy, hexoxy, etc. In another embodiment, it has 1 to 3 carbons and is composed of methoxy, ethoxy, n-propoxy and isopropoxy. The alkoxy group attached to the alkyl group is referred to as an alkoxyalkyl group. An example of an alkoxyalkyl group is methoxymethyl.

[0108] The term "alkoxyalkyl" as used herein refers to an alkyl group, as defined herein, substituted with an alkoxy group.

[0109] The term "cycloalkyl" refers to a carbocyclic substituent obtained by removing a hydrogen from a saturated or partially unsaturated (but not including aromatic rings) carbocyclic molecule, for example a carbocyclic molecule having 3 to 7 carbon atoms. The term "cycloalkyl" includes monocyclic saturated carbocyclic rings. The term "C 3 -C 7 "Cycloalkyl" refers to a group of 3 to 7 membered ring systems, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "Cycloalkyl" refers to a group of 3 to 7 membered ring systems, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. s -C s "Cycloalkyl" refers to a group of 3 to 6 membered ring systems, including cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl and cyclohexyl. Cycloalkyl can also be a bicyclic or spirocyclic carbocyclic ring. For example, the term "C 3 -C 12 "Cycloalkyl" includes monocyclic carbocyclic and bicyclic and spirocyclic cycloalkyl molecules such as dicyclopentyl, dicyclohexyl, bicycloheptyl, bicyclooctyl, bicycloalkenyl, spiropentyl, spirohexyl, spiroheptyl, spirooctyl and spiroranyl.

[0110] The term "cycloalkyl" refers to a divalent cycloalkyl group as defined herein.

[0111] The term "C 3 -C 6 "Cycloalkoxy" refers to a 3- to 6-membered cycloalkyl group attached to an oxy group. Examples include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

[0112] In some cases, the number of atoms in a ring substituent containing one or more heteroatoms (i.e., a heteroaryl or heterocycloalkyl) is represented by the prefix "x- to y-membered", where x is the minimum number of atoms forming the substituted ring molecule and y is the maximum number of atoms forming the substituted ring molecule. Thus, for example, "4 to 6 membered heterocycloalkyl" refers to a heterocycloalkyl containing 4 to 6 atoms (including 1 to 3 heteroatoms) in the ring molecule of the heterocycloalkyl. Similarly, the term "5 to 6 membered heteroaryl" refers to a heteroaryl containing 5 to 6 atoms and "5 to 10 membered heteroaryl" refers to a heteroaryl containing 5 to 10 atoms in a ring molecule of 30 heteroaryls, each of which includes one or more heteroatoms. In addition, the terms "5 membered heteroaryl" and "6 membered heteroaryl" may refer to a five-membered heteroaromatic ring system and a six-membered heteroaromatic ring system, respectively. The heteroatoms present in these ring systems are selected from N, O and S.

[0113] The term "hydroxy" (hydroxyl) refers to -OH. When used in combination with another term, the prefix "hydroxy" indicates that the substituent to which the prefix is ​​attached is replaced by one or more hydroxy substituents. Compounds having a carbon with one or more hydroxy substituents include, for example, alcohols, enols, and phenols. The terms cyano and nitrile refer to the -CN group. The term "oxo" refers to an oxygen attached to a carbon by a double bond (i.e., when R 4 When it is oxygen, R 4 Together with the carbon to which it is attached is a C=O molecule).

[0114] The term "hydroxyalkyl" refers to an alkyl group, as defined herein, substituted with 1, 2 or 3 hydroxy groups.

[0115] The term "halo" or "halogen" refers to fluorine (depicted as -F), chlorine (depicted as -Cl), bromine (depicted as Br), or iodine (depicted as -I).

[0116] The term "haloalkyl" refers to an alkyl group, as defined herein, substituted with 1, 2, 3, 4, 5, or 6 halo groups. In some embodiments, haloalkyl includes chloroalkyl.

[0117] The term "heterocycloalkyl" refers to a substituent obtained by removing a hydrogen from a saturated or partially saturated ring structure containing a total of the specified number of atoms, e.g., 4-6 ring atoms or 4-12 atoms, wherein at least one ring atom is a heteroatom (i.e., oxygen, nitrogen or sulfur) and the remaining ring atoms are independently selected from the group consisting of carbon, oxygen, nitrogen and sulfur. The sulfur may be oxidized [i.e., S(O) or S(O) 2] or is not oxidized. In a group having a heterocycloalkyl substituent, the heterocycloalkyl substituent ring atom to which the group is bound may be a nitrogen heteroatom or a ring carbon atom. Similarly, if a heterocycloalkyl substituent is in turn substituted by a group or substituent, the group or substituent may be bound to a nitrogen heteroatom or to a ring carbon atom. It is understood that a heterocyclic group may be monocyclic, bicyclic, polycyclic or spirocyclic.

[0118] The term "aryl" refers to a carbocyclic monocyclic or bicyclic ring system, wherein the monocyclic ring is aromatic and the bicyclic ring includes at least one aromatic ring. 6 -C 10 "Aryl" refers to a carbon ring system having 6 to 10 atoms, including phenyl, tetrahydronaphthyl and naphthyl. In addition to any groups specifically listed in any embodiment or claim, in some embodiments, aryl is optionally substituted with 1-3 substituents independently selected from halogen, -C 1-12 Alkyl (unsubstituted or substituted, in one embodiment with 1, 2 or 3 halogenated groups), aryl, -OH, -OC 1-12 Alkyl, -S(O) n C 1-4 Alkyl (where n is 0, 1 or 2), -C 1-4 Alkyl NH 2 、-NHC 1-4 Alkyl, -C(=O)H, C(=O)OR a 、-OC(=O)R b 、OC(=O)NR a R c , OC(=O)heteroaryl, C(=O)(heterocyclyl) and C=N-OR d , where R a , R c and R d are independently hydrogen or -C 1-4 Alkyl, and R b It is an alkyl group.

[0119] The term "arylene" as used herein refers to a divalent aromatic group as defined herein.

[0120] The term "heteroalkyl" refers to an alkyl group as defined herein, wherein one or more -CH 2 - is independently selected from -O-, -S-, -S(O)-, -S(O) 2 and -NR-, wherein R is hydrogen or alkyl, as defined herein, and / or one or more -CH 3 The groups are independently selected from -OH, -SH and -NH 2wherein each R is independently hydrogen or alkyl. Heteroalkyl includes 2-thioethyl, 2-amino-P-1-yl, 2-hydroxy-ethyl-1-yl, N-methyl-amino-ethyl, and the like. Hydroxyalkyl is a subset of heteroalkyl.

[0121] The term "heteroalkylene" refers to a divalent heteroalkyl group as defined herein.

[0122] The term "heteroaryl" refers to an aromatic ring structure containing a specified number of ring atoms, wherein at least one ring atom is a heteroatom (i.e., oxygen, nitrogen, and / or sulfur) and the remaining ring atoms are carbon. Examples of heteroaryl substituents include 6-membered heteroaryl rings, such as pyridyl, pyrazolyl, pyrimidinyl, and pyridazinyl; and 5-methylheteroaryl rings, such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazine, 1,2,5-oxadiazinyl, 1,3,4-oxadiazolyl, and isothiazolyl. Heteroaryl can also be a bicyclic heteroaryl, such as indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, oxazolopyridinyl, imidazopyridinyl, and imidazopyrimidinyl. In a group having a heteroaryl ring, the ring atom of the heteroaryl ring to which the group is bound may be a nitrogen atom or a ring carbon atom. Similarly, if the heteroaryl ring is in turn substituted with a group or a substituent, the group or substituent may be bound to the nitrogen atom or to the ring carbon atom. The term "heteroaryl" also includes pyridyl N-oxides and groups containing pyridine N-oxide rings. In addition, the heteroaryl group may contain an oxo group, such as the oxo group present in a pyridone group. Further examples include furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinediyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-acyl, pyridazin-2(1H)-acyl, pyrimidin-2(1H)-acyl, pyrazin-2(1H)-acyl, imidazo[1,2-a]pyridinyl and pyrazolo[1,5-propyridinyl]. Heteroaryl may be further substituted as defined herein.

[0123] Examples of monocyclic heteroaryl and heterocycloalkyl groups include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, isopyrazolidinyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolidinyl, imidazolinyl, pyrazolinyl, pyrazolidinyl, pyrazalidinyl, thiozolyl, tetrazolyl, dithio, oxathiolidinyl, isoxazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiazodiazolyl, oxathiazolyl, oxadiazolyl {including oxadiazolyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazinyl, 1,3,4-oxatriazolyl), pyranyl 1,2-pyranyl or 1,4-pyranoyl), dihydropyranyl, pyridyl, piperidyl, diazinyl (including pyridazinyl, pyrimidinyl, piperazinyl, triazinyl (including s-triazinyl, as-triazinyl and v-triazinyl), oxazinyl (including 2H-1,2-oxazinyl, 6H-1,3-oxazinyl, 2H-1,4-oxazinylbutyl, isoxazolidinyl (including O-isoxazolyl zincyl or p-isoxazolinyl), oxazolidinyl, isoxazolidinyl, oxathiazinyl (including 1,2,5-oxathiazinyl or 1,2,6-oxathiazinyl), oxadiazinyl (including 2H1,2,4-oxadiazinyl or 2H1,2,5-oxadiazinyl) and morpholinyl.

[0124] When so specified, the term "heteroaryl" may also include ring systems having two rings, wherein the rings may be fused and one of the rings is aromatic while the other ring is not completely part of a diconjugated aromatic system (i.e., the heteroaromatic ring may be fused to a cycloalkyl or heterocycloalkyl ring). Non-limiting examples of such ring systems include 5,6,7,8-tetrahydroisoquinolyl, 5,6,7,8-tetrahydroquinolyl, 6,7-dihydro-5H-cyclopentyl[b]pyridinyl, 6,7-dihydro-5-cyclopentyl[c]pyridinyl, 1,4,5,6-tetrahydrocyclopentyl[c]pyrazolyl, 2,4,5,6-tetrahydrocyclopentyl[c]pyrazolyl, 5,6-dihydro-4H-pyrazol ... pyrrolo[1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo[1,2-b[1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine, 4,5,6,7-tetrahydro-1H-indazolyl and 4,5,6,7-tetrahydroxy-2H-indolizinyl.

[0125] It should be understood that if a carbocyclic or heterocyclic molecule can be bonded or otherwise attached to a specified group through different ring atoms, without indicating a specific point of attachment, all possible points are referred to, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term "pyridyl" means 2-, 3-, 4-pyridyl, the term "thienyl" means 3- or 2-thienyl, and so on.

[0126] The term "heteroarylene" as used herein refers to a divalent heteroaryl group as defined herein.

[0127] The term "amino protecting group" refers to a group that prevents the amino from reacting when the other parts of the molecule react and can be easily removed. Non-limiting examples include 9-fluorenylmethoxycarbonyl, tert-butyloxycarbonyl, acetyl, benzyl, allyl, p-methoxybenzyl, etc. These groups can be optionally substituted by one to three substituents selected from halogen, alkoxy and nitro. The amino protecting group is preferably 9-fluorenylmethoxycarbonyl.

[0128] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.

[0129] The term "unsaturated" in the context of the terms cycloalkyl, cycloalkylene and heterocyclyl refers to a partially unsaturated but non-aromatic ring.

[0130] The term "fused" refers to a bicyclic, tricyclic or polycyclic structure composed of at least two carbocyclic or heterocyclic structures that share at least one chemical bond.

[0131] If a substituent is described as having more than one variable "independently," each instance of the substituent is independently selected from the list of available variables. Thus, each substituent may be the same as or different from the other substituents.

[0132] If a substituent is described as being "independently selected" from a group, each instance of the substituent is selected independently of the other instances. Thus, each substituent may be the same as or different from the other substituents.

[0133] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, "aryl optionally mono- or di-substituted with alkyl" means that alkyl may but need not be present, and that the description includes instances where aryl is mono- or di-substituted with alkyl and instances where aryl is not substituted with alkyl.

[0134] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1-3 hydrogen atoms, independently replaced by a corresponding number of substituents. Needless to say, substituents are present only in their possible chemical positions. Those skilled in the art can determine by experiment or theory whether substitution is possible or not without undue effort. For example, the combination of an amino or hydroxyl group with free hydrogen and a carbon atom with an unsaturated bond (such as an olefinic group) may be unstable.

[0135] As used in this application, the term "compound of formula (I)" (or other general formula numbering) is defined to include all forms of the compound of formula 1, including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs and metabolites thereof. For example, the compounds disclosed in the present application or pharmaceutically acceptable salts thereof may exist in undissolved and solvated forms. When the solvent or water is tightly bound, the complex will have a clear stoichiometry, regardless of humidity. However, when the solvent or water is weakly bound, such as in channel solvates and hygroscopic compounds, the water / solvent content will depend on humidity and drying conditions. In this case, non-stoichiometry will be the norm. Compounds with the same molecular formula but different atomic bonding properties or orders or different arrangements of atoms in space are referred to as "isomers". Isomers with different arrangements of atoms in space are referred to as "stereoisomers".

[0136] Stereoisomers that are not mirror images of one another are termed "diastereomers," while those that are non-superimposable mirror images of one another are termed "enantiomers." For example, when a compound has an asymmetric center, it binds to four different groups, and a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center, and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light, and designated as right- or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."

[0137] The compounds provided herein may have one or more asymmetric centers; such compounds may therefore be produced as individual (R)- or (S)-stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include its individual enantiomers and mixtures, racemates or other forms. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see "Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

[0138] Hydrogen (H) or carbon (C) substitution of the compounds of formula I includes substitution with any isotope of the corresponding atom. Thus, hydrogen (H) substitution includes 1 H. 2 H(deuterium) or 3H (tritium) isotope substitution may be desirable, for example, for specific therapeutic or diagnostic treatments, or metabolic research applications, or metabolic or chemical stability enhancement. Alternatively, the compounds of the present application may incorporate radioactive isotopes known in the art, such as 3 H. 15 O. 12 C or 13 N isotope to provide the corresponding radiolabeled compound of formula I.

[0139] "Pharmaceutically acceptable carrier" means a carrier that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, neither biologically significant nor otherwise undesirable, including carriers that can be used for veterinary and human pharmaceutical purposes. "Pharmaceutically acceptable carrier" as used in the specification and claims includes one or more such carriers.

[0140] A "pharmaceutically acceptable salt" of a compound refers to a salt that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts include: (1) Acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentene propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2- Hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, mucic acid, etc.; or (2) Salts formed when the acidic protons present in the parent compound are replaced by metal ions, such as alkali metal ions, alkaline earth ions or aluminum ions; or coordinated with organic bases such as ethanolamine, diethanolamine, triethanolamine, butanetriolamine, N-methylglucamine, etc.

[0141] "Treatment" for illness includes: (1) To prevent a disease, even if clinical symptoms of the disease will not develop in a mammal that may be exposed to or susceptible to the disease but does not yet experience or show symptoms of the disease, (2) inhibit the disease, i.e., prevent or reduce the development of the disease or its clinical symptoms, or (3) Relieve the disease, that is, cause the disease or its clinical symptoms to disappear.

[0142] The term "pharmaceutical composition" refers to a mixture of one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs with other chemical components, and other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism, which is beneficial to the absorption of the active ingredient, thereby showing biological activity.

[0143] The term "solvate" refers to a pharmaceutically acceptable solvate formed by the ligand-drug conjugate of the present application and one or more solvent molecules. Non-limiting examples of solvent molecules include water, ethanol, acetonitrile, isopropanol, DMSO, ethyl acetate.

[0144] The term "carrier" used in the composition of the present application refers to a system that can change the way a drug enters the human body and is distributed, control the drug release rate, and deliver the drug to the target organ. The drug carrier release and targeting system can reduce drug degradation and loss, reduce side effects, and improve bioavailability.

[0145] The term "excipient" refers to the auxiliary materials in pharmaceutical preparations other than the main drugs, which can also be called adjuvants, such as binders, fillers, disintegrants, and lubricants in tablets; the matrix part in semi-solid preparations ointments and creams; preservatives, antioxidants, flavorings, fragrances, solubilizers, emulsifiers, solubilizers, osmotic pressure regulators, colorants in liquid preparations, etc.

[0146] The term "diluent", also known as filler, is mainly used to increase the weight and volume of the tablet. The addition of diluent ensures a certain volume, reduces the dosage deviation of the main ingredients, and improves the compression characteristics of the drug. When the tablet contains oily ingredients, absorbents are added to absorb the oily substances, thereby maintaining a "dry" state to facilitate tablet formation. For example, diluents include starch, lactose, inorganic salts of calcium, microcrystalline cellulose, etc.

[0147] The pharmaceutical composition can be in the form of a sterile injectable aqueous solution. Acceptable carriers or solvents that can be used are water, Ringer's solution or isotonic sodium chloride solution. The sterile injectable preparation can be a sterile injectable oil-in-water microemulsion, in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and treated to form a microemulsion. The injectable solution or microemulsion can be introduced into the patient's blood by local bolus injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compound of the present application. In order to maintain this constant concentration, a continuous intravenous delivery device can be used. Deltec CADD-PLUS TM The 5400 IV Pump is an example of such a device.

[0148] The pharmaceutical composition can be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration. Such suspensions can be prepared with suitable dispersants or wetting agents and suspending agents as described above according to known techniques. Sterile injectable preparations can also be sterile injectable solutions or suspensions prepared in nontoxic parenteral acceptable diluents or solvents, such as solutions prepared in 1,3-butanediol. In addition, sterile fixed oils can be easily used as solvents or suspension media. For this purpose, any mixed fixed oils can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids, such as oleic acid, can also be used to prepare injections.

[0149] The term "drug loading" refers to the average number of cytotoxic drugs loaded on each ligand in the compound of formula (I), and can also be expressed as the ratio of the number of drugs to the number of antibodies. The drug loading of each ligand can be in the range of 0 to 12, preferably 1 to 10 cytotoxic drugs. In the embodiments of the present application, the drug loading is expressed as n, and exemplary values ​​can be an average value of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. The average number of drugs per ADC molecule after the coupling reaction can be determined by conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA testing and HPLC characterization.

[0150] "Therapeutically effective amount" refers to the amount of a compound sufficient to treat a disease when administered to a mammal to treat the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc. of the mammal to be treated.

[0151] The term "mammal" refers to all mammals, including humans, livestock, and companion animals.

[0152] The compounds described herein are generally named according to the IUPAC or CAS naming system. Abbreviations well known to those of ordinary skill in the art can be used (e.g., "Ph" means phenyl, "Me" means methyl, "Et" means ethyl, "h" means hours, and "rt" or "rt" means room temperature). Synthesis method of the present application

[0153] Solution 1

[0154] The method for preparing the compound of formula (VI) of the present application or a pharmaceutically acceptable salt or solvate thereof comprises the following steps: The compound of formula (D1) is reacted with the compound of formula (D2), optionally under basic conditions, to obtain a compound of formula (VI); Where: Y, Z, R 1 , R 2 , R 3 , R4 , R 5 , R 6 , R 7 , R 8 、n 1 、n 2 , n is as defined in formula (VI) and any of its embodiments.

[0155] The reagents providing alkaline conditions include organic bases and inorganic bases. Organic bases include, but are not limited to, triethylamine, diethylamine, N-methylmorpholine, pyridine, piperidine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, and potassium tert-butoxide. Inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, and lithium hydroxide.

[0156] Solution 2

[0157] A method for preparing a compound of formula (D7) according to formula (V) of the present application or a pharmaceutically acceptable salt or solvate thereof comprises the following steps: Step 1: optionally reacting a compound of formula (D1) and a compound of formula (D3) under alkaline conditions to obtain a compound of formula (D4); Step 2: Deprotecting the compound of formula (D4) to obtain a compound of formula (D5); Step 3: reacting a compound of formula (D5) with a compound of formula (D6) in the presence of a condensing agent or under alkaline conditions, and optionally under alkaline conditions, to obtain a compound of formula (D7), in: PG is an amino protecting group, preferably benzyloxycarbonyl (Cbz); Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 12 , R 13 , R 14 , S 1 、n 1 、n 2 , n is as defined in formula (V) and any of its embodiments.

[0158] The reagents providing alkaline conditions include organic bases and inorganic bases. Organic bases include, but are not limited to, triethylamine, diethylamine, N-methylmorpholine, pyridine, piperidine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, and potassium tert-butoxide. Inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, and lithium hydroxide.

[0159] The condensing agent is selected from 4-(4.6-dimethoxy-1.3.5-triazine-2-yl)-4-methyl-morpholine chloride, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride, N,N'-dicyclohexylcarbodiamide, N,N'-dipropylcarbodiamide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-benzotriazole-N-,N,N' , N'-tetramethyluronium hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, benzotriazole-1-acyloxytris(dimethylamino)-hexafluorophosphate and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, preferably 4-(4.6-dimethoxy-1.3.5-triazine-2-yl)-4-methyl-morpholine chloride, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride.

[0160] Solution 3

[0161] A method for preparing a compound of formula (D8) according to formula (IV) of the present application and any embodiment thereof or a pharmaceutically acceptable salt or solvate thereof, comprising the following steps: After reduction, T is coupled with the compound of formula D7 to obtain a ligand-drug conjugate of formula (D8); the reducing agent is preferably TCEP; wherein: T is the ligand; Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 12 , R 13 , R 14 , W, n 1 、n 2 , n, and m are as defined in formula (IV) or any of its embodiments.

[0162] The present application will be further described with reference to the following examples, but these examples should not be construed as limiting the scope of the present application. The experimental methods in the present application examples that do not specify specific conditions are carried out according to conventional conditions or conditions recommended by material or product manufacturers. Reagents that do not specify specific sources are conventional reagents purchased from the market. Example

[0163] Example 1

[0164] To a solution of 1-1 (300 mg, 0.700 mmol) in DMSO (5 mL) was added NaN at 25 °C. 3 (120 mg, 1.85 mmol). The reaction mixture was then stirred at 25 °C for 12 h. LCMS showed that 1-1 was completely consumed and the expected product was detected. 2 The reaction mixture was diluted with H2O (30 mL) and filtered. 2 O (15 mL × 3) and dried under reduced pressure to obtain a yellow solid crude product 1-2 (240 mg, 0.551 mmol, yield 78.8%). LC-MS: 436.1 [M+H] + .

[0165] At 25°C, triethyl phosphite (181 mg, 1.09 mmol) was added to a toluene (6 mL) solution of 1-2 (190 mg, 0.436 mmol). The reaction mixture was heated to 120°C and stirred for 12 hours. The reaction mixture was then cooled to 25°C and HCl / MeOH (4 mol / L, 3 mL) was added. The reaction mixture was heated to 80°C and stirred for 12 hours. TLC (PE / EA=1 / 1) showed that 1-2 was completely consumed, and a new spot was detected by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was slurried with EA (5.0 mL) at 25°C. Yellow solid 1-3 (80.0 mg, 0.179 mmol, 41.2% yield) was obtained.

[0166] At 25°C, N 2 To a mixture of 1-3 (50.0 mg, 0.112 mmol), 1-4 (70.9 mg, 0.224 mmol) and DIEA (28 μL, 0.168 mmol) in DCM (2 mL) was added AcOH (0.016 mL, 0.280 mmol) and NaBH(OAc) 3 (94.61 mg, 0.449 mmol). The reaction mixture was then heated to 400 °C under N 2The reaction mixture was stirred for 12 hours. LCMS showed that 1-3 was completely consumed and the expected product MS was detected. The reaction mixture was washed with brine (5 mL×2) and washed with Na 2 SO 4 The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to give yellow solid compound 1 (16.9 mg, 0.034 mmol, yield 30.5%).

[0167] Example 2

[0168] Pyrrolidin-3-ol (7.31 mg, 0.08 mmol) and DIEA (0.04 mL, 0.21 mmol) were added to a solution of 1-1 (30.00 mg, 0.07 mmol) in DMF (3.00 mL), and the mixture was stirred at 20 ° C for 12 hours. LCMS showed that the reaction was complete. The reaction mixture was purified by prep-HPLC to give a yellow solid compound 2 (2.87 mg, 0.01 mmol, 8.94% yield).

[0169] The following compounds were synthesized according to the procedure described in Example 2.

[0170] Embodiment 36

[0171] To a solution of trichloroborane (18.6 mL, 18.6 mmol) in DCE (5.00 mL) at 0 °C, 36-1 (3.00 g, 19.85 mmol) was added in proportion, the mixture was stirred for 10 minutes, and then 2-chloroacetonitrile (1.51 mL, 23.8 mmol) and AlCl 3(3.47 g, 26.0 mmol). The mixture was stirred at 20 °C for 20 minutes, then heated to 75 °C and stirred for 11 hours. LC-MS showed that 36-1 was completely consumed, and a major peak with the expected molecular weight was detected. The reaction mixture was cooled to 0 °C, the pH was adjusted to 1 with 2N HCl, and stirred for 1 hour. The aqueous phase was extracted with DCM (50.0 mL×3). The combined organic phases were washed with brine (30.0 mL) and washed with anhydrous Na 2 SO 4 Dry, filter, and concentrate the filtrate. The residue was purified by prep-HPLC to obtain a yellow solid 36-2 (1.30 g, 5.71 mmol, yield 28.8%). LC-MS: 228.0 [M+H] + , rt = 0.587 min.

[0172] To a solution of 36-2 (200 mg, 1.12 mmol) in toluene (5.00 mL) was added 36-3 (231 mg, 0.879 mmol) and 4-methylbenzene-1-sulfonic acid (7.56 mg, 0.0440 mmol) at 25 °C. The mixture was stirred at 110 °C for 12 hours. LC-MS showed that 36-2 was completely consumed and a major peak with the expected molecular weight was detected. The reaction mixture was cooled to room temperature, filtered, and the solid was dried under reduced pressure. The crude product was slurried with ethyl acetate (10 mL) at 25 °C for 3 hours to give a brown solid 36-4 (380 mg, 0.835 mmol, yield 95.1%). LC-MS: 455.1 [M+H] + , rt = 0.844 min.

[0173] To a solution of 36-4 (50.0 mg, 0.110 mmol) in DMF (2.00 mL) at 0°C, (R)-1-(piperidin-4-yl)ethanol-1-ol hydrochloride (21.5 mg, 0.13 mmol) and DIEA (77 μL, 0.440 mmol) were added. The mixture was stirred at 25°C for 15 minutes. LC-MS showed that 36-4 was completely consumed, and a major peak with the expected molecular weight was detected. The mixture was purified by prep-HPLC to give a yellow solid compound 36 (13.7 mg, 0.0250 mmol, yield 22.8%).

[0174] The following compounds were synthesized according to the procedure described in Example 36.

[0175] Example 43

[0176] 43-1 (110 mg, 0.29 mmol) was suspended in CF 3 COOH (3.5 ml) and H 2 SO 4 (1.2 ml) of the mixture. Add FeSO 4 7H 2 O (0.21 g, 0.76 mmol) and H 2 After cooling to 5°C, HCONH 2 (0.2 ml). 65% (CH 3 ) 3 COOH (0.1 ml, 0.68 mmol). The mixture was stirred at 0°C for 1 hour and then poured into ice water. The precipitated material in the solution was collected by suction, washed with water and dried in vacuo. A yellow powder 43-2 (0.100 g, yield: 96.1%) was obtained.

[0177] To a solution of 43-2 (43 mg, 0.11 mmol) and piperidin-4-ylmethanol (75 mg, 0.65 mmol, 0.328 mol) in 2 mL of DMSO was added concentrated hydrochloric acid (0.1), and the mixture was heated at 140 °C for 1 hour. H 2 O (4 mL), and then filtered. The filtrate was loaded onto 4 mL of activated HP-20 resin and heated with H 2 O until the pH value of the eluent reaches 6. Then eluted with 20% methanol-dichloromethane solution to obtain the product. The solvent was evaporated and the residue was purified by SGC (DCM / MeOH=10:1) to obtain 11 mg of yellow solid compound 43 (yield 21%).

[0178] Embodiment 49

[0179] To a solution of 49-1 (15 g, 56.3 mmol) and Py (5.70 mL, 70.4 mmol) in THF (60 mL) and toluene (180 mL) was added Pb(OAc) at 25 °C. 4(35.0 g, 78.9 mmol), and the mixture was stirred at 80 ° C for 12 hours. TLC (P / E=0 / 1) showed that 49-1 was completely consumed. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by SGC (petroleum ether / ethyl acetate=10 / 1 to 1 / 1). A light yellow solid 49-2 (6.80 g, 24.3 mmol, yield 43.1%) was obtained.

[0180] To a DMF (10 mL) solution of 49-3 (1.00 g, 2.96 mmol) and 49-2 (1.08 g, 3.85 mmol) at 25 ° C, TosOH (0.03 g, 0.148 mmol) was added. The reaction mixture was heated to 60 ° C and stirred for 12 hours. TLC (PE / EA = 0 / 1) showed that most of 49-3 was consumed and a major spot was detected. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by SGC (petroleum ether / ethyl acetate = 50 / 1 to 0 / 1). A yellow solid 49-4 (1.00 g, 1.79 mmol, yield 60.5%) was obtained.

[0181] At 25 ° C, diethylamine (1.86 mL, 17.9 mmol) was added to a solution of 49-4 (1.00 g, 1.79 mmol) in DCM (10 mL), and the mixture was stirred for 12 hours. LCMS showed that 49-4 was completely consumed, and the expected product MS was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC. A yellow oil 49-5 (270 mg, 0.805 mmol, yield 44.9%) was obtained.

[0182] To a mixture of 49-5 (340 mg, 0.793 mmol) and 1-1 (265.91 mg, 0.793 mmol) in DMF (3 mL) was added DIEA (307 mg, 2.38 mmol) at 0°C. The reaction mixture was heated to 25°C and stirred for 15 minutes. HPLC showed that 49-5 was completely consumed. The reaction mixture was purified by prep-HPLC. A yellow solid 49-6 (110 mg, 0.151 mmol, 19.1% yield) was obtained.

[0183] At 25℃, N 2 To a solution of 49-6 (110 mg, 0.151 mmol) in 2,2,2-trifluoroethane-1-ol (5.0 mL) was added Pd / C (30.0 mg, 0.282 mmol). The resulting suspension was degassed and heated to 40 ℃. 2 (15 psi) purged 3 times, then at 25 ° C, H 2(15Psi) and stirred for 2 hours. LCMS showed that 49-6 was completely consumed and the expected product MS was detected. The reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC. A yellow solid 49-7 (30.0mg, 0.042mmol, yield 28.1%) was obtained. LC-MS: 594.3[M+H] + .

[0184] At 25 ° C, DIEA (16.3 mg, 0.126 mmol) was added to a mixture of 49-7 (30.0 mg, 0.042 mmol) and compound 49-8 (96.6 mg, 0.085 mmol) in DMF (2.0 mL), and the mixture was stirred for 12 hours. LCMS showed that 49-7 was completely consumed, and the expected product MS was detected. The mixture was purified by prep-HPLC. Yellow solid compound 49 (4.39 mg, 0.004 mmol, yield 9.88%) was obtained.

[0185] The following compounds were synthesized according to the procedure described in Example 49.

[0186] Embodiment 57

[0187] Embodiment 61

[0188] 61-7 was prepared by the same method as 49-7.

[0189] To a solution of 61-1 (1.90 g, 4.32 mmol) in THF (30.0 mL) was added NaH (0.260 g, 6.48 mmol) at 0°C, and the mixture was stirred for 1 hour, followed by the addition of tert-butyl 2-bromoacetate (1.01 g, 5.19 mmol). The reaction mixture was slowly heated to 25°C and stirred for 2 hours. TLC (EA) showed that SM was completely consumed, and one major spot was detected. The reaction mixture was washed with saturated NH 4 The mixture was quenched with Cl solution (50 mL) and then with H 2The combined organic layers were washed with brine (20 mL x 2) and washed with Na 2 SO 4 After drying and filtering, the filtrate was concentrated under reduced pressure. The residue was purified by SGC (petroleum ether / ethyl acetate=100 / 1 to 0 / 1) to give yellow oil 61-2 (1.30 g, 2.35 mmol, yield 54.3%).

[0190] In N 2 To a solution of 61-2 (1.00 g, 1.81 mmol) in EtOAc (10.0 mL) was added Pd / C (10%, 0.100 g, 0.903 mmol). The resulting suspension was degassed under vacuum and heated to 40°C. 2 The reaction mixture was then heated at 25 °C and H 2 (0.0400 g, 18.1 mmol) (15 psi) and stirred for 4 hours. LCMS showed that SM was completely consumed and the expected product MS was detected. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain a yellow oily crude product 61-3 (900 mg, 1.71 mmol, yield 94.4%). LC-MS: 528.4 [M+H] + .

[0191] To a mixture of 61-3 (900 mg, 1.706 mmol) and (1r, 4r)-4-[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid (486 mg, 2.05 mmol) in DCM (10.0 mL) was added DIEA (0.9 mL, 661 mg, 5.12 mmol) and BOP (1.13 g, 2.56 mmol) at 25 ° C, and the reaction mixture was stirred for 12 hours. LCMS showed that SM was completely consumed and the expected product MS was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (water (FA)-ACN, Phenomenex luna C18 (250*70 mm, 15 um)) to give 61-4 (400 mg, 0.536 mmol, yield 31.4%) as a yellow oil. LC-MS: 747.35[M+H] + .

[0192] A DCM solution (5.00 mL) of 61-4 (400 mg, 0.536 mmol) and TFA (1.00 mL) were stirred at 25 ° C for 12 hours. LCMS showed that SM was completely consumed and the expected product MS was detected. The reaction mixture was concentrated under reduced pressure to give a yellow oil 61-5 (370 mg, 0.536 mmol, crude product). LC-MS: 691.35 [M+H] + .

[0193] At 25°C, DIC (24.7 mg, 0.195 mmol) was added to a solution of 61-5 (135 mg, 0.195 mmol) and HOSu (22.5 mg, 0.195 mmol) in DMF (5.00 mL). The mixture was then stirred for 12 hours and filtered. DIEA (50.5 mg, 0.391 mmol) and 61-6 (54.6 mg, 0.195 mmol) were added to the filtrate at 25°C, and the reaction mixture was then stirred for 12 hours. LCMS showed that SM was completely consumed and the expected product MS was detected. The reaction mixture was purified by prep-HPLC (water (FA)-ACN, Phenomenex Luna C1875*30mm*3um) to give a yellow oil 61-7 (100 mg, 0.105 mmol, yield 53.7%). LC-MS: 952.4 [M+H] + .

[0194] At 25 ° C, to a mixture of 61-7 (35.0 mg, 0.037 mmol) and 61-6 (22.3 mg, 0.037 mmol) in DMF (3.00 mL) were added NMM (0.012 mL, 0.110 mmol) and DMTMMT (12.7 mg, 0.040 mmol), and the reaction mixture was stirred for 12 hours. LCMS showed that SM was completely consumed and the expected product MS was detected. The reaction mixture was purified by prep-HPLC (water (FA)-ACN, Phenomenex Luna C1875*30mm*3um). An off-white solid 61 (20.0 mg, 0.012 mmol, yield 32.6%) was obtained.

[0195] The following compounds were synthesized according to the procedure described in Example 61.

[0196] Example 67: Preparation of antibody-drug conjugates (such as ADC-1)

[0197] Antibodies for Exemplary ADCs

[0198] The antibodies of the example ADC compounds were prepared according to conventional methods, such as vector construction, eukaryotic cell transfection, such as HEK2943 cell (Life Technologies Cat. No. 11625019) transfection, purification and expression. The prepared antibodies include trastuzumab light chain (SEQ. ID NO. 1), trastuzumab heavy chain (SEQ. ID NO. 2), pertuzumab light chain (SEQ. ID NO. 3), pertuzumab heavy chain (SEQ. ID NO. 4), B7H3 antibody light chain (SEQ. ID NO. 5) and B7H3 antibody heavy chain (SEQ. ID NO. 6).

[0199] General process of coupling

[0200] At 37°C, the prepared tris(2-carboxyethyl)phosphine aqueous solution (10 mM, 0.082 mL, 0.82 μmol) was added to the antibody PBS buffered aqueous solution (0.05 M PBS buffered aqueous solution, pH = 6.5; 2.5 mL, 9.96 mg / mL, 0.168 umol). The reaction solution was placed in a water bath shaker and shaken at 37°C for 3 hours, and then the reaction was stopped. The reaction solution was cooled to 25°C in a water bath and diluted to 5.0 mg / ml. 2.0 ml of the solution was taken for the next reaction.

[0201] Linker-camptothecin compound (2.1mg, 2.02umol) is dissolved in 0.10mL DMSO, then added in 2.0ml above-mentioned solution.The reaction solution is placed in a water bath shaker, and the reaction is stopped after oscillation at 25°C for 3 hours.The reaction solution is desalted and purified with a dextran G25 gel column (elution phase: 0.05M PBS buffered aqueous solution, pH=6.5, containing 0.001MEDTA), to obtain the PBS buffer solution of the exemplary product ADC, which is stored at 4°C.

[0202] The drug loading analysis (UV method) of ADC was performed according to the method of U.S. Patent Application Publication No. US2021 / 0353764 (i.e., paragraph

[0702] ff).

[0203] The drug loading of ADC was analyzed (LC-MS method) according to the method of US Pat. No. 11,572,414 (i.e., column 2, line 51 to column 3, line 15).

[0204] ADC aggregation levels were determined by size exclusion chromatography (SEC). All samples were filtered through 0.22 μm filters prior to HPLC-SEC analysis.

[0205] The HPLC method was performed as follows: Instrument: Thermo Ultimate 3000 Column: Waters, XBridge BEH SEC 3.5μm(7.8×300mm) Mobile phase: PBS containing 15% isopropanol, pH 7.4 Flow rate: 0.5 ml / min, 30 minutes.

[0206] The following ADCs were synthesized according to the general procedure described in Example 67.

[0207] Embodiment 68

[0208] In vitro cytotoxicity assay of camptothecin payload

[0209] The human lung adenocarcinoma cell line A549 was used to evaluate the cytotoxicity of the small molecule fragments of the present invention. A549 cells were seeded into 96-well plates at 2000 cells per well. The cells were incubated at 5% CO 2 After overnight incubation at 37°C, serially diluted compounds were added. After 3 days, cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay Kit produced by Promega Corp. according to the manufacturer's instructions. The results are shown in Table 1 below.

[0210] Table 1 Cytotoxicity of the compound of formula (VI) to A549 cells.

[0211] As shown in Table 1, the compounds of Examples 15, 19, 22, 27, 31, 32, and 33 were 5-6 times more potent than the control compound (Dxd). Surprisingly, some minor structural changes significantly affected cytotoxicity. For example, although the amide moiety was well tolerated in Dxd, the lactam analog of Example 1 was much less potent than most other amine analogs. The 3-OH substituted piperidine compound of Example 17 was the most potent compound among the other quaternary, pentacyclic, or hexacyclic analogs of Examples 2, 9, and 16. 2The OH-substituted piperidine compounds of Examples 10, 11, and 12 are also less effective than Example 17. In addition, the S-isomers of Examples 17 and 19 are also more effective than Example 17. As shown in Examples 15, 27, 31, 32, and 33, increasing lipophilicity may increase cell permeability and may also improve efficacy. However, these molecules may also have lower solubility, which may lead to an increase in aggregates during antibody coupling, as evidenced by the high aggregation and low DAR values ​​in the synthesis of ADC-4 and ADC-5. Although the aggregation problem can be improved by using a hydrophilic PEG-like linker, this will increase the difficulty of preparation and may compromise efficacy. For example, Examples ADC-8 and ADC-9 in Table 2 are less effective than Example ADC-3.

[0212] Embodiment 69

[0213] In vitro cytotoxicity assay of ADCs

[0214] Cancer cell lines with different Her2 expression levels, including NCI-N87, Calu-3, SK-BR-3, CAPAN-1, and CFPAC-1 cells, were used to test the cytotoxicity of the ADC of the present invention. These cell lines were seeded into 96-well plates at 1000-4000 cells per well. The plates were incubated at 5% CO 2 After overnight incubation at 37°C, serially diluted compounds were added. After 6 days, cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay Kit produced by Promega Corp. according to the manufacturer's instructions. The results are shown in Table 2 below.

[0215] Table 2 In vitro cytotoxicity assay of ADCs.

[0216] Calu-3, NCI-N87 and SK-BR-3 are all Her2-high-expressing cancer cell lines, and CAPAN-1 and CFPAC-1 are reported as Her2-low-expressing cell lines. The ADC of the present invention, such as ADC-3, exhibits considerable cytotoxicity in Her2-high-expressing cancer cell lines, but surprisingly, has significantly higher potency in Her2-low-expressing cell lines. Among similar analogs, ADC-3 has the strongest effect on the NCI-N87 cell line.

[0217] Embodiment 70

[0218] In vitro bystander killing of ADCs

[0219] The target cells SK-BR-3 and the GFP-labeled tool cells Flip in 293mGFP were inoculated or mixed and cultured for 1 day, and treated with ADC-3 solution diluted 4 times in series for 5 days (mixed cells were prepared by mixing these two cells and inoculating at 40 μL / well, the final density of SK-BR-3 was 750 cells / well, and the final density of Flip in 293mGFP was 250 cells / well). At the end of the treatment, the number of live Flip in 293mGFP cells was determined by high content screening (HCS) in the DPC and FITC channels. Figure 1 As shown, the tool cell Flip in 293mGFP stably expresses green fluorescent protein (GFP). When inoculated alone, no significant reduction of Flip in 293mGFP cell counts was observed, but when the cells were co-cultured, at the same concentration of ADC, Flip's cell count in 293mGFP was reduced, showing a bystander killing effect.

[0220] Embodiment 71

[0221] In vitro plasma stability study of ADC

[0222] A 1.6 mg / mL solution of ADC-3 was prepared and added to human plasma, and the resulting mixture was incubated at 37°C. 40 uL samples were taken at each time point of 0, 6, 18, 24, 72, and 96 hours. After normal processing, the plasma samples were tested for free payload by LCMSMS method. Figure 2 As shown, the ADC released less than 0.5% of its payload in plasma over a period of up to 4 days, indicating that the ADC of the present invention has good stability in human plasma.

[0223] The LCMSMS method has the following characteristics: Instrument: Thermo Orbitrap Exploris240 Column: ACQUITY BEH C18 1.7μm(2.1×150mm) Mobile phase: ACN containing 0.1% FA Flow rate: 0.3ml / min

[0224] Embodiment 72

[0225] In vivo efficacy studies of ADCs

[0226] The NCI-N87 cell line was used to create the CDX (cell line derived xenograft) NCI-N87 xenograft mouse model. Each 6-8 week old nu / nu nude mouse was injected subcutaneously into the right flank with 10 7The injection site was palpated three times a week until the average tumor size reached 300 mm as measured by digital calipers. 3 Animals were randomly divided into treatment groups. ADC-2 and ADC-3 were injected intravenously once at a dose of 3 mg / kg. Tumor size was measured and recorded weekly.

[0227] like Figure 3 As shown in the results, ADC treatment significantly suppressed tumor growth after treatment. Despite comparable in vitro cytotoxicity, ADC-3 showed better efficacy than ADC-2 in the NCI-N87 mouse model. With a single dose of treatment, mice in the ADC-3 group had stable disease for nearly 2 months, much longer than the ADC-2 group. Importantly, in Figure 4 In the experiment, the mice in the ADC-3 group (the last eight bars in the figure) had a higher response rate and better tumor regression on day 21 compared with the ADC-2 group (the first eight bars in the figure). No tumor development was observed in the ADC-3 group. Therefore, the significant improvement in the in vivo efficacy of the example ADC-3 compound was completely unexpected and very surprising.

[0228] Full representative data ( Figure 3 and Figure 4 ) reveal the surprisingly superior therapeutic potential of the compounds described in the present application, with beneficial unexpected advantages in terms of efficacy, efficacy and bystander killing. The significant and surprising improvement in the in vivo efficacy of ADCs provided in the present application provides significant benefits for the treatment of humans or mammals, including but not limited to better clinical cure rates, reduced effective drug doses and reduced possible adverse reactions.

Claims

1. A ligand-drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises a structure of formula (IIa): in: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each "C 1 -C 8 "alkyl" is independently optionally substituted by 1-3 R 9 replace; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 Alkyl)C(O)O-, (C 1 -C 8 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; X 1 does not exist; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 Contains one or more independently selected from -O-, -S-, -NH-, C 1- C 8 Alkylene, C 3 -C 6 Cycloalkylene, arylene and heteroarylene groups; wherein X 2 Connected to formula (IIa) The terminal group is O or S; C 1 -C 8 Alkylene, C 3 -C 6 Each of the cycloalkylene, arylene and heteroarylene groups is independently optionally substituted with 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or When X 1 and R 5 When no ring is formed, R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form a carbonyl, a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 Replace; and the remaining R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 4 R 9 replace; R 9 Each occurrence is independently selected from halogen, oxo, hydroxy, cyano, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 When the groups are attached to the same carbon, they form a spiro-C 3 -C 6 Cycloalkyl; wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C 1 -C 3 Alkyl substitution; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4; provided that n 1 +n 2a is 2, 3 or 4; Provided that the claim does not include the following substructures:

2. The ligand-drug conjugate according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein : Y and Z are independently selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; R 3 Selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; X 1 does not exist; X 2 is-O-; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H, halogen and C 1 -C 8 alkyl; n 1 and n 2a are each independently an integer selected from 0, 1, 2 and 3; provided that n 1 +n 2a It is 2, 3 or 4.

3. The ligand-drug conjugate according to claim 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, in, It is a ligand-drug conjugate of formula (IIIa) or a pharmaceutically acceptable salt or solvate thereof: in: R 1 and R 2 Each is hydrogen; T is the targeting or binding ligand; L is a releasable linker; m is an integer or a fraction selected from 1 to 10.

4. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 3, wherein : is a structure selected from the following: Optionally, wherein: is a structure selected from the following:

5. The ligand-drug conjugate according to any one of claims 3 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein m is an integer or fraction selected from 2 to 8; optionally, m is an integer or fraction selected from 3 to 8.

6. The ligand-drug conjugate according to any one of claims 3 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein L is -L 1 -L 2 -L 3 -L 4 -, and optionally wherein L 1 connected to the ligand, and L 4 Connect to X 2 And X 2 is -O-; and L 1 Selected from the group consisting of: -CH 2 -C(O)-NR 10 -WC(O)-, -C(O)-WC(O)-, and -W-, where W and W 1 Independently selected from the group consisting of: C 1 -C 8 Alkylene, -(C 1 -C 8 alkylene)-cycloalkylene, arylene, heteroarylene and straight-chain heteroalkylene, wherein the straight-chain heteroalkylene contains 1 to 8 carbon atoms and 1 to 3 heteroatoms selected from N, O, S, SO and SO 2 wherein said-(C 1 -C 8 Each of the following groups is independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the above-provided L 1 The left side of each of the groups is connected to T; L 2 Selected from the group consisting of: -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds, where p 1 is an integer selected from 1 to 20 at each occurrence; L 2 Preferably a chemical bond; wherein L provided 2 The left side of the group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; in, The above provided L 3 The left side of each group is connected to L 2 ; L 4 Selected from the group consisting of: -NR 12 (CR 13 R 14 ) t -、-C(O)NR 12 -、-C(O)NR 12 (CH) t -、 and a chemical bond, wherein t at each occurrence is an integer selected from 1 to 6; L 4 Preferably -NR 12 (CR 13 R 14 ) t ; where L provided above 4 The left side of each group is connected to L 3 on the right side, and L 4 The right side of each of the groups is attached to X 2 ; R 10 , R 11 and R 12 are each independently selected from H, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 13 and R 14 are each independently selected from H, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 is selected from -CH 2 CH 2 SO 2 CH 3 and -CH 2 CH 2 N(CH 3 ) 2 ; Optionally, L 1 is selected from the group consisting of: -CH 2 -C(O)-NR 10 -(CH 2 )s 3 -C(O)- (where the left side of the group is attached to T), -C(O)- (CH 2 )s 4 -C(O)- (where the left hand side of the group is attached to T) and -C 6 H 4 -, where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; s 3 is an integer selected from 1 to 8; s 4 is an integer selected from 1 to 8; and / or Optionally, where L 2 Selected from the group consisting of: -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds, where p 1 is, at each occurrence, an integer selected from 6 to 12; and / or Optionally, L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), glutamic acid (E) and aspartic acid (N); preferably a peptide residue consisting of 1, 2 or more phenylalanine and glycine; more preferably a peptide residue consisting of 4 amino acids; most preferably a peptide residue consisting of GGFG; and / or Optional L 4 For-NR 12 (CR 13 R 14 ) t -, R 12 is H or alkyl, R 13 and R 14 Each is independently selected from H and alkyl, t is 1 or 2; L 4 Optionally -NR 12 CR 13 R 14 -;L 4 Preferably -NHCH 2 -.

7. The ligand-drug conjugate according to any one of claims 3 to 6, or a pharmaceutically acceptable salt or solvate thereof, wherein L is -L 1 -L 2 -L 3 -L 4 -, L 1 yes L 2 It is a chemical bond; L 3 It is a peptide residue containing 4 amino acids; L 4 Yes - NR 12 (CR 13 R 14 ) t -、R 12 is H or alkyl, R 13 and R 14 Each is independently H or alkyl, and t is 1 or 2.

8. The ligand-drug conjugate according to any one of claims 3 to 6, or a pharmaceutically acceptable salt or solvate thereof, wherein L is -L 1 -L 2 -L 3 -L 4 -, L 1 yes L 2 is - NR 11 (CH 2 CH 2 O) 9 CH 2 CH 2 C(O)-; L 3 It is a peptide residue containing 4 amino acids; L 4 Yes - NR 12 (CR 13 R 14 ) t -、R 12 is H or alkyl, R 13 and R 14 Each is independently H or alkyl, and t is 1 or 2.

9. The ligand-drug conjugate according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, selected from:

10. The ligand-drug conjugate according to any one of claims 3 to 9, or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate is a compound according to formula (IIIa) or a pharmaceutically acceptable salt or solvate thereof: wherein T is a targeting antibody or ligand that binds to an antigen; wherein the antibody is selected from a chimeric antibody, a humanized antibody, and a human antibody; and optionally wherein T is a monoclonal antibody; or Wherein T is selected from anti-Her2 (ErbB2) antibody, anti-EGFR antibody, anti-B 7 H 3 Antibodies, anti-c-MET antibodies, anti-Her3 (ErbB3) antibodies, anti-Her4 (ErbB4) antibodies, anti-CD20 antibodies, anti-CD22 antibodies, anti-CD30 antibodies, anti-CD33 antibodies, anti-CD44 antibodies, anti-CD56 antibodies, anti-CD70 antibodies, anti-CD73 antibodies, anti-CD105 antibodies, anti-CEA antibodies, anti-A33 antibodies, anti-Cripto antibodies, anti-EphA2 antibodies, anti-G250 antibodies, anti-MICI antibodies, anti-Lewis Y antibodies, anti-VEGFR antibodies, anti-GPNMB antibodies, anti-integrin antibodies, anti-PSMA antibodies, anti-Tenascin-C antibodies, anti-SLC44A4 antibodies or anti-mesothelin antibodies, and anti-ROR1 antibodies or antigen-binding fragments thereof; or Wherein T is selected from Trastuzumab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96 and Glembatumumab, or a fragment that binds to an antigen.

11. The ligand-drug conjugate according to any one of claims 3 to 10, or a pharmaceutically acceptable salt or solvate thereof, selected from:

12. A compound of formula (Va) or a pharmaceutically acceptable salt or solvate thereof: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each "C 1 -C 8 "alkyl" is optionally substituted by 1 to 3 R 9 replace; Each R 1 and each R 2 Independently selected from H, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl; or each pair of R 1 and R 2 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each R 1 , R 2 and R 1 / R 2 The ring groups are independently optionally substituted with 1 to 4 R 9 Substituted; optionally, wherein each R 1 and each R 2 Each is H; n 3 is an integer selected from 0 to 6; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 Alkyl)C(O)O-, (C 1 -C 8 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; X 1 Does not exist; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 including one or more independently selected from -O-, -S-, -NH-, C 1 -C 8 Alkylene, C 3 -C 6 A group among cycloalkylene, arylene and heteroarylene; wherein X 2 Connect to L 4 The terminal group is O or S; 1 -C 8 Alkylene, C 3 -C 6 Cycloalkylene, arylene and heteroarylene are each independently optionally substituted by 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or When X 1 and R 5 When no ring is formed, R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form a carbonyl, a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl are each independently optionally substituted with 1 to 4 R 9 Replace; and the remaining R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 4 R 9 replace; R 9 Each occurrence is independently selected from halogen, oxo, hydroxy, cyano, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 The group consisting of alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 When the groups are attached to the same carbon, they form a spiro-C 3 -C 6 Cycloalkyl; wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C 1 -C 3 Alkyl substitution; n 1 and n 2a Each is an integer independently selected from 0, 1, 2, 3 and 4; provided that n 1 +n 2a is 2, 3, or 4; and n is an integer selected from 0 and 1; W is selected from the group consisting of: C 1 -C 8 Alkylene, -(C 1 -C 8 alkylene)-cycloalkylene, arylene, heteroarylene and straight-chain heteroalkylene, wherein the straight-chain heteroalkylene contains 1 to 8 carbon atoms and 1 to 3 heteroatoms selected from N, O, S, SO and SO 2 wherein said-(C 1 -C 8 Each of the alkylene)-cycloalkyl-, straight chain heteroalkylene, arylene and heteroarylene groups is independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from the group consisting of: -NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 C(O)-、-NR 11 (CH 2 CH 2 O) p 1 CH 2 CH 2 -、-NR 11 (CH 2 CH 2 O) p 1 CH 2 C(O)-、-S(CH 2 ) p 1 C(O)- and chemical bonds, where p 1 is an integer selected from 1 to 20 at each occurrence; L 2 Preferably a chemical bond; wherein each L 2 The left side of the group is connected to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl and deuterated alkyl; wherein each L 3 The left side of the group is connected to L 2 ; L 4 Selected from the group consisting of: -NR 12 (CR 13 R 14 ) t -、-C(O)NR 12 -、-C(O)NR 12 (CH) t -、 and a chemical bond, wherein t at each occurrence is an integer selected from 1 to 6; L 4 Preferably -NR 12 (CR 13 R 14 ) t ; where each L 4 The left side of the group is connected to L 3 on the right side, and each L 4 The right side of the group is connected to X 2 ; R 10 , R 11 and R 12 are each independently selected from H, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 13 and R 14 are each independently selected from H, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 is selected from -CH 2 CH 2 SO 2 CH 3 and -CH 2 CH 2 N(CH 3 ) 2 ; Provided that the claim does not include a substructure:

13. The compound according to claim 12, in, It is selected from the following structures:

14. A compound of formula (VIIa) or a pharmaceutically acceptable salt thereof or optionally as a tautomer, mesomer, racemate, enantiomer, enantiomer or mixture thereof: in: Y and Z are independently selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, (C 1 -C 8 alkyl)C(O)O- and (C 1 -C 8 or Y and Z together with the atoms to which they are attached form a group containing 1 to 3 atoms independently selected from N, O, S, S(O) and S(O) 2 wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, 5 to 8 membered heterocycloalkyl, 5 to 8 membered heteroaryl and each "C 1 -C 8 "alkyl" is independently optionally substituted by 1-3 R 9 replace; R 3 Selected from the group consisting of H and halogen, hydroxy, cyano, C 1 -C 8 Alkyl, C 1 -C 8 Alkoxy, (C 1 -C 8 Alkoxy)-C 1 -C 8 Alkyl, amino, (C 1 -C 8 Alkyl)amino, (C 1 -C 8 Alkyl)NHC(O)O-, (C 3 -C 6 Cycloalkyl)NHC(O)O-, (C 1 -C 8 Alkyl)C(O)O-, (C 1 -C 8 alkyl)C(O)NH-, aryl, heteroaryl and nitro; wherein each "C 1 -C 8 "Alkyl", cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 3 R 9 replace; X 1 Does not exist; or X 1 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or X 1 and R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is optionally substituted by 1 to 3 R 9 replace; X 2 Contains one or more independently selected from -O-, -S-, -NH-, C 1- C 8 Alkylene, C 3 -C 6 Cycloalkylene, arylene and heteroarylene groups; wherein X 2 Connect to –X 2 The terminal group of H in -H is O or S; C 1 -C 8 Alkylene, C 3 -C 6 Each of the cycloalkylene, arylene and heteroarylene groups is independently optionally substituted with 1 to 3 R 9 replace; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Each of cycloalkyl, aryl and heteroaryl is independently optionally substituted by 1 to 4 R 9 replace; or When X 1 and R 5 When no ring is formed, R 4 and R 5 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 4 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 6 and R 7 Together with the atoms to which they are attached, they form a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; or R 7 and R 8 Together with the atoms to which they are attached, they form a carbonyl, a 3- to 6-membered cycloalkyl or a 4- to 8-membered heterocycloalkyl; wherein each of the 3- to 6-membered cycloalkyl and the 4- to 8-membered heterocycloalkyl is independently optionally substituted by 1 to 4 R 9 Replace; and the remaining R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H and halogen, hydroxy, C 1 -C 8 Alkyl, C 3 -C 6 The group consisting of cycloalkyl, aryl and heteroaryl, wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, aryl and heteroaryl are independently optionally substituted by 1 to 4 R 9 replace; R 9 Each occurrence is independently selected from halogen, oxo, hydroxy, cyano, C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl and heteroaryl; or two R 9 The groups, when attached to adjacent carbons, together with the carbons to which they are attached, form a fused C 3 -C 6 Cycloalkyl; or two R 9 When the groups are attached to the same carbon, they form a spiro-C 3 -C 6 Cycloalkyl; wherein C 1 -C 8 Alkyl, C 3 -C 6 Cycloalkyl, C 1 -C 8 Alkoxy, aryl, heteroaryl, fused C 3 -C 6 Cycloalkyl and spiro C 3 -C 6 Each of the cycloalkyl groups is optionally independently substituted with 1 to 3 fluorine or hydroxyl groups and C 1 -C 3 Alkyl substitution; n 1 and n 2a are each independently an integer selected from 0, 1, 2, 3 and 4; provided that n 1 +n 2a is 2, 3 or 4; Provided that the claim does not include the following substructures: Optionally, wherein: Y and Z are independently selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; R 3 Selected from H, halogen, C 1 -C 8 Alkyl and C 1 -C 8 Alkoxy; X 1 does not exist; X 2 is-O-; R 4 , R 5 , R 6 , R 7 and R 8 is independently selected at each occurrence from H, halogen and C 1 -C 8 alkyl; n 1 and n 2a Each is an integer independently selected from 0, 1, 2 and 3; provided that n 1 +n 2a It is 2, 3 or 4.

15. The compound according to claim 14, in: is a structure selected from the following: Optionally, wherein: is a structure selected from the following:

16. The compound according to claim 14 or 15, in, It is selected from the following structures:

17. A pharmaceutical composition comprising a therapeutically effective amount of a ligand-drug conjugate according to any one of claims 1 to 11 or a pharmaceutically acceptable salt or solvate thereof; or a compound according to any one of claims 14 to 16 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier, diluent or excipient.

18. A method for treating cancer, the method comprising administering to a subject in need thereof a ligand-drug conjugate according to any one of claims 1 to 11 or a pharmaceutically acceptable salt or solvate thereof; or a compound according to any one of claims 14 to 16 or a pharmaceutically acceptable salt or solvate thereof; or a pharmaceutical composition according to claim 17; optionally wherein the cancer is a tumor; optionally wherein the cancer is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer cancer, including ovarian cancer, pancreatic cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer, ovarian cancer,

Citation Information

Cited By

  • A novel conjugate, method and use thereof

    WO2026214703A1